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ABSTRACT
REGULATION OF VASCULAR SMOOTH MUSCLE CELL
PHENOTYPE
Joshua K Salabei,
October 30, 2012
Vascular injury and chronic arterial diseases such as atherosclerosis and
restenosis result in exposure of vascular smooth muscle cells (VSMCs) to
increased concentrations of growth factors triggering a change from a contractile to
a synthetic phenotype. The mechanisms by which growth factors trigger VSMC
phenotype transitions remain unclear. Because phenotype switching involves the
removal of contractile proteins, we hypothesized that autophagy is an essential
modulator of VSMC phenotype. Also, the conversion to the synthetic phenotype is
accompanied by cellular changes that trigger metabolic changes to meet the
increasing demands for cellular energy. Little is known however about the
contributions of different substrates metabolized for energy production and how
these metabolic changes

integrate with

phenotype switching

and VSMC

proliferation. We further hypothesize that metabolic changes induced by PDGF are
required for phenotype switching and proliferation. Studies presented here show
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that: 1) Treatment of VSMCs with platelet-derived growth factor PDGF-BB results
in activation of autophagy which is required for degradation of contractile proteins
during phenotype switching; 2) Increased glycolytic flux caused by PDGF
treatment is required for expression of the synthetic cytokine osteopontin and for
proliferation; and 3) Mitochondria fragmentation and increased fatty acid oxidation
are required for PDGF-induced VSMC proliferation.
These results support the overall hypothesis that autophagy and changes in
intermediary metabolic pathways are modulators of PDGF-induced phenotype
transition. Our findings suggest that autophagy-directed therapies may provide
effective treatments against vascular diseases such as atherosclerosis and
restenosis.
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CHAPTER 1
GENERAL INTRODUCTION
ROLE OF VASCULAR SMOOTH MUSCLE CELLS IN VASCULAR DISEASES

Despite advances in modern medicine, cardiovascular disease (CVD) remains
the leading cause of mortality in the United States accounting for 35% of all
deaths with about 1 in 3 American adults having one or more type of CVD [1].
According to the CDC, the total costs related to CVD in 2008 were in excess of
$450 billion, and these are expected to increase in the future [1-4]. Although
CVD-related deaths have declined in high income countries, mortality have
increased in low and middle income countries [5]. These differences in mortality
due to CVDs are attributable to modifiable risk factors such as healthy eating,
exercise, air pollution, and smoking [6].
Cardiovascular diseases encompass all diseases affecting the cardiovascular
system, which include the heart and peripheral blood vessels. One of the most
common CVD is atherosclerosis, i.e., the buildup of cholesterol in the artery walls
of blood vessels supplying the heart (coronary heart disease) or supplying the
peripheral tissues (peripheral arterial disease) [7]. The onset of atherosclerosis
begins early in life from childhood whereby there is a gradual deposition of
cholesterol and oxidized low density lipoprotein (LDL) in the subintima of arteries
leading to the formation of an atherosclerotic plaque. Plaque formation is caused
1

by macrophage-stimulated inflammatory reactions that ultimately leads to plaque
rupture (or thrombosis) [8]. Thrombosis may lead to heart attack and/or stroke,
which are ranked amongst the top three major causes of death in the United
States [9].
Physiology of the healthy human artery: The mature healthy human artery is

made up of 3 principal layers: the intima-composed of endothelial cells (ECs),
the media-composed of primarily vascular smooth muscle cells (VSMCs) and
the adventitia-composed of fibroblasts and connective tissues (Scheme 1). The
complexity of the human artery has developed over time because the need for an
efficient blood delivery system became needed as organisms became more
complex. The different layers of the arteries have thus evolved to meet the needs
of supplying oxygen and nutrients to distal organs and tissues. The endothelium
is a thin layer of ECs allowing diffusion of important factors from blood to
underlying layers and tissues. The media layer is found underneath the
endothelium and it is composed of fully differentiated vascular smooth muscle
cells, which express a repertoire of contractile proteins such as a-smooth muscle
actin. Thus, the principal function of the media is contraction and regulation of
vessel tone and blood flow. This layer is innervated by the sympathetic and
parasympathetic nervous systems and therefore the regulation of this layer is
tightly controlled [10-11]. Beneath the media is the adventitia, comprised mostly
of fibroblasts and connective tissues. This layer provides mechanical support and
stability to the blood vessels.
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The

formation

of

nascent

blood

vessels

occurs

via

two

processes;

vasculogenesis, the formation of nascent blood vessels, and angiogenesis, the
sprouting of new blood vessels from existing blood vessels. Expression of
Vascular Endothelial Growth Factor (VEGF) is critical during vasculogenesis and
angiogenesis [12]. VEGF-A stimulates the CD31+ and CD34+ VEGF receptorpositive angioblasts to initiate vessel formation and set in motion molecular
events that eventually lead to mature a vascular network [13]. VEGF-A stimulates
angioblasts to differentiate into endothelial cells forming nascent tubes [14]. The
endothelial layer in nascent tubes and mature blood vessels is usually a single
cell thick, allowing for rapid exchange of materials between blood and underlying
tissues. The nascent endothelial tubes formed after VEGF stimulation are
stabilized by cells of the mural compartment, particularly VSMCs. Under the
influence of platelet derived growth factor (PDGF) and other growth factors such
as transforming growth factor 13 (TGF-I3), VSMCs form an outer layer beneath the
endothelial cells. This stabilization is followed by extracellular matrix (ECM)
deposition [15]. At the level of small arteries, i.e., arterioles, smooth muscle cell
organization is relatively simple with a single smooth muscle cell wrapped
completely around the lumen of the nascent endothelial tube [16]. In larger
arteries where there are multiple smooth muscle cell layers, VSMCs are
arranged close to perpendicular with the axis of blood flow [16]. This
arrangement aids lengthening of blood vessels during high pressure thus
regulating vessel tone and blood distribution. Beneath the media layer of VSMCs
is the adventitia layer composed of fibroblasts and other ECM components. The
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main function of the adventitia is structural because it attaches the blood vessel
to the basement membrane; however, the adventitia is increasingly recognized to
play non-structurally related functions because changes in this layer were
amongst the earliest structural changes found in diseased vessels [17].
Atherosclerosis involves the buildup of cholesterol and oxidized LDL in the
artery wall: During atherogenesis, accumulation of cholesterol and oxLDL in the

subintima space of the artery [18-19] leads to recruitment of monocytes (from
the circulation) through cell junctions of the endothelial layer into the subintimal
space [16-17] (Scheme 2). In the subintima, monocytes differentiate into
macrophages and continuously take up excess lipids while failing to return into
circulation (i.e., impaired efferocytosis). This repeated failure of the innate
immune responses to clear subintimal LDL results in the deposition of lipidloaded macrophages (foam cells) which in turn induces vascular inflammation in
the vessel wall [20]. Foam cell formation is also thought to occur through VSMC
engulfment of subintimal lipids [21-22]. Most often, lesions are covered and
stabilized by VSMCs which are thought to migrate from the media layer to form a
neointima or protective cap [21-22]. However, continuous failure to clear foam
cell macrophages and increased vascular inflammation beneath such caps
progressively leads to weakening of the protective cap. Such advanced lesions
when present in areas of high stress, for example in arterial branches, often lead
to plaque rupture and thrombosis leading to heart attack or stroke.

4

Scheme 1

Cross sectional area of a human artery
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The majority of atherosclerotic lesions in humans go unnoticed because of the
formation of the neointima that covers and stabilizes these lesions [23]. In cases
where the formation of the neointima is thick enough to hinder blood flow through
a vessel, slight chest pain or angina is often felt [24]. In other cases where there
is severe or complete obstruction of blood flow (such as after thrombosis),
angioplasty, a mechanical surgical intervention, is used to widen the obstructed
artery after which a (drug eluting) stent is placed to prevent VSMC proliferation.
However, re-occlusion (or restenosis) of previously opened (restored) arteries
characterized by excessive proliferation of underlying VSMCs that migrate
luminally and form a neointima is common [25-26]. For example, a study with a
total of 1,012 patients who were randomly assigned treatment with sirolimuseluting (n

= 503)

or paclitaxel-eluting stents (n

= 509)

showed that -28% of

subjects needed revascularization at some later time [27]. Although the outcome
of such clinical studies depends on the demographics of the population in
question (such as the presence of diabetes), it highlights restenosis as an
important question that continually warrants our attention. Endothelial damage
caused by angioplasty or diseased conditions is thought to cause increased
exposure of underlying VSMCs to growth factors such as PDGF and other
cytokines resulting in their migration (from the media) and hyperproliferation in
the neointimal region [28]. Currently, drug-eluting stents (DES) are often placed
in arteries after the plaque has been cleared, the goal of which is to inhibit VSMC
proliferation and restenosis. However, despite these interventions, restenosis
continues to be problematic especially in certain classes of patients such as
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those suffering from diabetes, where the restenotic process is more severe, often
leading to increased neointima formation and total vessel occlusion [29-31]. This
can result in increased incidence of myocardial infarction, heart failure [32] and
vasculopathy, which contribute significantly to morbidity and mortality ascribed to
diabetes [33-35].
Phenotype switching in VSMCs: VSMCs in healthy arteries express a
repertoire of contractile proteins, signaling molecules and ion channels required
for their contractile function [36]. A number of SMC-specific contractile genes
have been used to identify the contractile phenotype. These include smooth
muscle isoforms of a-actin (SM-a-actin), SM myosin heavy chain (SM-MHC),
calponin, SM22a and smoothelin [37-45]. Although these SMC marker genes are
expressed in the differentiated phenotype, they are also transiently expressed in
other cell types during development, disease progression and tissue repair [46].
Because of this, multiple marker genes are required for rigorous identification of
fully differentiated VSMCs, and no one SMC marker gene can exclusively be
used for the identification of VSMCs.
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Unlike skeletal and cardiac muscle cells, which are terminally differentiated [47],
VSMCs have a unique characteristic of plasticity that enables them to switch to a
less contractile or synthetic phenotype (de-differentiation). The synthetic
phenotype is typically characterized by loss of expression of contractile proteins
and increased expression of synthetic proteins such as osteopontin [28, 48].
However, there appears to be a phenotype gradient between the contractile and
synthetic phenotypes, such that, depending on environmental cues, VSMCs can
develop features of both phenotypes or reverse their phenotype from a dedifferentiated to a contractile phenotype [49].
Many factors regulate the development or maintenance of the contractile and
synthetic phenotypes. Some of these factors have been summarized in Table 1.
Synergistic effects of signals or synergistic effects of multiple pathways on VSMC
dedifferentiation have also been reported. For example, it was shown that PDGF
and IL 1-13 can act synergistically to promote the development of the synthetic
phenotype [50]. Extracellular matrix proteins such as polymerized collagen have
been shown to cause down regulation of genes such as thrombospondin and
fibronectin, which are known to be upregulated in injured vessels [51]. Other in
vitro studies have further confirmed that VSMCs cultured on a fibronectin coated

surfaces are induced to become more synthetic, while when cultured on a
laminin-rich surface, their contractile phenotype is maintained [52-53].

The

effects of these different ECM proteins on VSMC phenotype is known to be
mediated through integrin-cell surface receptors. Wang et al [54] showed that the
ECM cartilage oligomeric matrix protein (COMP) maintained VSMCs in their
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contractile phenotype and the effects of COMP were mediated through
intergrin, a major laminin receptor in VSMCs.

07131

The role of growth factors in

regulating VSMC phenotypes has also been extensively studied. Transforming
growth factor beta, insulin growth factor-1 and angiotensin are known examples
that promote the contractile phenotype (see Table 1). In contrast, basic fibroblast
growth factor (bFGF) and PDGF promote the synthetic phenotype, although only
PDGF has been identified as a factor that can selectively and directly promote
phenotypic modulation of VSMCs [55-56].
PDGF as a mitogen and an inducer of VSMC phenotypic switching: The
platelet derived growth factors (PDGFs) constitute key mitogens for cell types of
mesenchymal origin including smooth muscle cells. The PDGFs comprise a
family of four different polypeptides, which include PDGF-A, B, C and D. These
polypeptides form homo- or hetero-dimers with five known dimeric isoforms:
PDGF-AA, AB, BB, CC and DD. PDGF-A and B are known to heterodimerize
while PDGF-C and D only form homodimers [57] (Scheme 3). The PDGFs signal
through tyrosine kinase receptors, i.e., PDGFR-o and PDGFR-I3. Both PDGFR-o
and

-13 can

form homo or heterodimers that can be activated to varying degrees

by the PDGFs [57]; however, PDGF-BB has been shown to be one of the most
potent forms to activate the PDGFR signaling cascade, leading to VSMC
dedifferentiation and proliferation [58]. PDGF-BB, to date, is the most potent
stimulator of VSMC proliferation, migration and phenotype switching [56].
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Effects on SMC
phenotype

Factor

Growth factors
• PDGF-BB
• bFGF
• Angiotensin II
• Transforming growth factor
• Insulin and IGF-1

•
•
•

Promotes
Promotes
Promotes
Promotes
Promotes

•
•
•

Promotes synthetic
Promotes contractile
Promotes synthetic

• [66-67]
• [68]
• [50,69]

•
•

Promotes contractile
Promotes synthetic

• [70-74]
• [75-76]

•

Promotescontractile
Maintains contractile
Promotes synthetic
Promotes contractile

•
•
•
•

•

Promotes synthetic
Maintains contractile
Promotes synthetic

• [79]
• [80]
• [81]

•

Promotes contractile
Promotes contractile
Promotes contractile

• [82-83]
• [84]
• Unpubli
shed

•
•

Injury/atherogenic stimuli
• Oxidized phospholipids
• ROS
• Cytokines
MicroRNAs
• miRs 145, 143, 195, 25, 1
• miRs 21,221,222,126
Basement matrices
• Monomeric collagen
• Polymeric collagen
• Fibronectin
• Matrigel

•
•
•

Extracellular matrix components
• ADAMST7
• Cartilage oligomeric matrix protein
• Osteopontin

•
•

Pharmocoligical inhibitors
• Rapamycin
• Lovastatin
• Spautin1

•
•

Table1: Factors regulating VSMC phenotypes
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synthetic
synthetic
contractile
contractile
contractile

Reference(s)

•
•
•
•
•

[58-59]
[60-61]
[62]
[63-64]
[65]

[50]
[50]
[77]
[78]

PDGF signals via multiple pathways: In the VSMC, PDGF-BB signals
principally through PDGFR-j3j3 and activates several biological pathways
responsible for VSMC growth and dedifferentiation [85]. These pathways have
also been shown to play a role in the pathogenesis of diseases such as
atherosclerosis and restenosis [49]. PDGF-BB activates the Akt, Erk1/2 and p38
MAPKs, as well as the JNK pathways. Activation of the Erk1/2 and Akt pathways
is known to play important roles in PDGF-induced VSMC proliferation, migration
and phenotype switching [50]. The activation of the other MAPKs by PDGF also
has profound effects on SMC behavior. Zhan et al [86] infected VSMCs with AdDN-p38 or Ad-DN-JNK and found that PDGF-induced SMC migration was
suppressed by 81 %, and 77%, respectively. Zhan et al also showed that Ad-DNp38 inhibited neointima formation after balloon injury of a rat carotid. This role of
p38 MAPK in neointima formation was independently confirmed by Proctor et al
[87].
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Scheme 3

PDGF-AA

PDGF-CC

PDGF-AB

PDGF-DD

PDGF-BB

PDGF receptor type

Platelet derived growth factors and platelet derived growth factor receptors
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Multiple pathways and transcription factors are required for PDGF-induced
phenotype

switching

and

proliferation:

PDGF-BB-induced

phenotype

switching in VSMCs occurs, in part, through transcriptional regulation of
promoters upstream of SMC marker genes resulting in their down regulation. A
critical transcription factor controlling expression of VSMC marker genes is
serum response factor (SRF). SRF binds to CC(AIT-rich)6GG (CArG) boxes in
the promoter regions of VSMC marker genes to control their expression [88].
CArG boxes are also present in the promoter regions of genes involved in ECM
production, migration and proliferation of VSMCs [89]. This suggests that any
factor that affects SRF binding to its response element is likely to affect multiple
genes that regulate cell phenotype. SRF utilizes coactivators such as myocardin,
which is expressed exclusively in SMCs and cardiomyocytes [90]. Generally,
myocardin forms a complex with SRF on CArG boxes to promote contractile
gene expression [90]

(Scheme 4). In its simplest model, SRF is seen as a

platform molecule that, when bound to the CArG box, recruits other molecules to
form complexes. These complexes either activate or suppress expression of
SMC marker genes.

PDGF is known to suppress complex formation of

myocardin and SRF and thus promotes the down regulation of contractile gene
expression [91] (Scheme 4). Simultaneously, PDGF promotes complex formation
of SRF with other transcription factors such as Elk-1, which is also known to play
a role in down regulating VSMC contractile gene expression [91].
Another important transcription factor known to play a role in PDGF-induced
VSMC dedifferentiation is Kruppellike factor 4 (Klf4) [92-95]. Klf4 is up-regulated
14

upon PDGF stimulation, and siRNA suppression of Klf4 was shown to inhibit
PDGF-induced down-regulation of contractile genes [96]. This regulation of
transcription factors is one level of control regulating VSMC phenotype switching.
CArG boxes in promoter regions are epigenetically marked with distinctive
patterns of posttranslational modifications in the form of histone methylations and
acetylations [58, 97]. These modifications regulate cis and trans DNA elements
also necessary for the control of expression of smooth muscle cell marker genes
[98]. In addition to regulating transcription factors, PDGF-BB is also known to
alter these posttranslational modifications through decreased histone (H4)
acetylation [99].
Phenotype switching induced by PDGF is accompanied by changes in ECM
components: The synthetic phenotype of VSMCs is characterized by increased
ECM secretion which is known to play an important role during cap formation in
atherosclerosis [36]. During phenotype switching, PDGF induces changes in
ECM components such as MMPs [100] and plasminogen activator inhibitor
protein 1 (PAI-1) [86]. An important class of MMPs affected by PDGF and known
to affect the progression of atherosclerosis and restenosis is the disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS). Members of the
ADAMTS family bind to and degrade other ECM components. ADAMTS-7, in
particular,

increases after balloon

injury of the carotid

artery,

and

its

overexpression exacerbates neointima formation [101] (see Table 1). An
important ECM protein degraded by ADAMTS-7 is COMP (or cartilage oligomeric
matrix protein) [102]. Unlike ADAMTS-7, COMP expression decreases after
15

balloon injury and its overexpression inhibits neointima formation [102]. COMP is
known to interact with the integrin receptor a7131 thereby indicating that the
intergrin receptors play important roles during PDGF-induced VSMC changes.
The alteration of the ECM also serves the purpose of releasing growth factors
and promoting VSMC migration during vascular remodeling under pathology.
PDGF-induced osteopontin expression is important in VSMC remodeling: A

key synthetic gene in the context of vascular disease induced upon PDGF
stimulation is osteopontin (OPN) [103]. OPN is also known as bone sialoprotein
1(8SP-1) or secreted phosphoprotein 1 (SPP1) and is secreted by other cell
types like macrophages and endothelial cells [104]. OPN is a cytokine with
autocrine effects and is thought to play important roles in VSMC proliferation
during atherosclerosis [105].
formation [103, 105-106].

Its levels are also increased during neointima

In fact, it has been shown that ablation of OPN in

female APOF'- mice completely prevented the formation of atherosclerotic
plaques [107]. Leali et al [108] showed that overexpressing OPN prevented reendothelization via intergrin engagement and that endothelial cells grown on an
OPN-rich basement showed reduced wound healing [108]. OPN is also
associated with aortic abdominal aneurysm (AAA), the weakening and bulging of
blood vessels due to excessive apoptosis of VSMCs in the media. Using
microarray analysis, Zheng et al [109] found that OPN was the highest expressed
gene in AAA tissues collected from patients who had no atherosclerosis but
underwent AAA repair operations. Zheng and colleagues found that OPN
stimulated autophagy in these patients and prolonged stimulation of autophagy
16

Scheme 4

PDGF-BB

Platelet-derived growth factor-BB
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led to type II cell death of VSMCs. The autophagy induced by OPN was
mediated through an integrin/CD44 and p38 MAPK-mediated pathway [11 OJ.
In patients suffering from diabetes, OPN is known to playa role in increased
vascular calcification. It has been proposed that the metabolic alterations of
diabetes are responsible for the increase in vascular calcification in these
patients [111-112]. Because dysregulated glucose metabolism plays a key role in
the development of diabetes, it was hypothesized that glucose regulates OPN
expression. Based on this hypothesis and using gel mobility shift assays, Bidder
et al [113] identified upstream stimulatory factor (USF) and activator protein-1
(AP1) as important regulators of OPN gene expression. The levels of USF and
AP1

were in turn controlled

by glucose metabolism.

Mannitol and 2-

deoxyglucose failed to produce the same effects. A few years later, Berglund et
al [114] specifically implicated the role of nuclear activator of T cell (NFAT) in
hyperglycemia-dependent regulation of OPN expression in VSMCs. These
studies suggest that glucose metabolism plays a key role in OPN expression and
perhaps in PDGF-induced OPN gene induction. How glucose metabolism
regulates OPN expression remains unclear.

Evidence of phenotype switching in atherosclerosis and restenosis: Several

studies support the idea that conversion of smooth muscle cells to a synthetic
phenotype plays an important role in vascular disease. For example, time
dependent down regulation of a-sm-actin was observed in autopsied tissue
samples from atherectomy patients and from patients undergoing transluminal
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coronary angioplasty indicating that there was at least some change in SMC
phenotype different from the contractile found in healthy blood vessels [115-116].
This finding in humans was later reproduced in experimental models of rabbit
atherosclerosis. Aikawa et a/ [117] found that contractile genes were down
regulated in the media and outermost edge of atheromas in these animals. The
expression of these contractile genes showed a time dependent increase in
experimental groups undergoing extensive lipid lowering treatment for 16 months
after induction of atheroscelerosis. This suggests that SMCs became more
contractile

after

lipid

lowering

and

this

corresponded

to

decreased

atherosclerosis. A profound finding in this study is that the lipid lowering
treatment caused marked reductions in ECM proteins such as MMPs and
VSMCs acquired an appearance of the contractile phenotype characterized by
few secretory organelles such as the golgi and endoplasmic reticulum.
Further supporting a role of phenotypic remodeling, other studies have reported
that intimal SMCs undergo changes such as increased DNA synthesis,
expression of proliferating markers such as PCNA and cyclins, decrease
expression of contractile genes (other than a-sm-actin) and alteration of cell
ultrastructure [118-120]. In 2001 it was shown that pharmacological inhibitors of
PDGF receptors could inhibit VSMC proliferation, migration and neointima
investment [121]. This experiment was not conclusive in providing clear evidence
as to the role of PDGF in atherosclerosis because the unwanted side effects of
the use of chemical inhibitors could not be rigorously ruled out. Later in 2002,
using a different approach, a direct role of PDGF-induced phenotypic modulation
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began emerging clearly. Kozaki ef al [122] administered PDGFR blocking
antibodies to ApoE-I- mice on a Western diet and found that there was up to 67%
reduction in atherosclerotic lesion size with reduced SMG investment in the
neointima.
The majority of studies have thus focused on identifying signaling and
transcriptional

mechanisms

regulating

phenotype

switching

in

diseased

conditions. For example, Wamhoff ef al [123] showed that mutation of a GIG
repressor in the 5' region of the GArG element of SM22a promoter and other
SMG marker gene promoters abolished the downregulation of SMG marker
genes in ApoE-I- mice on Western diet. The GIG repressor binds to the
transcription factor KLF4 and interestingly PDGF-induced SMG marker gene
repression is dependent on KLF4 binding to the GIG repressor [66, 92]. In ApoE1- animals on Western diet, KLF4 expression was markedly increased within
lesions [67]. Also, KLF4 overexpression strongly inhibited the expression of
myocardin, the coactivator necessary for SMG marker gene expression
meanwhile conditional knockdown of KLF4 transiently delayed the repression of
SMG marker genes in ApoE-I- animals on high fat diet [124-125]. These findings
therefore suggest a hypothesis whereby PDGF-induced phenotype switching
during atherogenesis occurs via KLF4 binding to the GIG repressor of SMG
marker genes thereby causing repression (Scheme 4). Few studies have looked
at postranscriptional changes such as protein degradation and how these
changes could impair phenotype switching.
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Protein degradation during phenotype switching and in vasculo-proliferative
disorders: In order to maintain homeostasis, mammalian cells need to balance

synthetic and degradative processes. Cellular degradation in mammalian cells is
carried out by two well described mechanisms: the proteasomal and autophagic
pathways [126-128].
Few studies addressing the role of the proteasomal pathway in vascular smooth
muscle cell remodeling and proliferation during arterial disease have been
reported. For example, the proteasomal inhibitors lactalysin and MG132 inhibited
VSMC proliferation in culture and after arterial injury in an animal model of
restenosis [129-130]. These inhibitors were found to stall cells at the S-phase of
cell cycle probably through up-regulation of the cell cycle inhibitor p21. However, it
has not been determined whether these drugs inhibited phenotype switching,
which is generally thought to precede VSMC proliferation.
The role of autophagy in atherosclerosis has also been documented. For example,
it was recently reported that inhibiting autophagy in macrophages by silencing
ATG5 or other autophagy mediators led to both increased apoptosis and plaque
instability in advanced lesions [131-132], which increases the risk of MI. Perhaps,
ablation of autophagy in these macrophages led to the accumulation of damaged
materials (e.g.,

misfolded

proteins,

damaged

mitochondria) that triggered

apoptosis. Such a finding indicates a beneficial role of autophagy in atheroclerosis.
Autophagy is known to playa protective role in the VSMC in lesions. For example
autophagy is known to be protective against cholesterol and HNE-induced toxicity
[133-134]. Autophagy was found to be responsible for the degradation of protein21

HNE adducts thus increasing the survival of VSMCs. However, the response to
HNE-induced toxicity or HNE-protein adduct formation in the different phenotypic
states has never been thoroughly studied. Since synthetic VSMCs are the
abundant phenotypes present in atherosclerosis, a prediction will be that these
synthetic VSMCs are more resistant to oxidative insults, thus explaining their
survival in this harsh oxidative environment. Also, since there is rapid turnover
during phenotype conversion, autophagy might serve the purpose of degrading
cellular

components,

releasing

metabolic

intermediates

needed

by

the

metabolically demanding synthetic cell [135].
PDGF-induced phenotype switching and proliferation is accompanied by
metabolic changes: Proliferating cells require, in addition to ATP, large amounts
of nucleotides, amino acids and lipids. Glucose and glutamine are principal
substrates used for the production of ATP as well as intermediates critical for the
synthesis of important biomolecules [136-137]. Although the hydrolysis of ATP is
needed for important biochemical reactions important during proliferation,
additional requirements also have to be met. For example, synthesis of fatty
acids requires more equivalents of carbon and NADH than of ATP [138]. Total
metabolism of a glucose molecule can generate up to 36 ATPs. This number of
ATP molecules far exceeds the amount needed to synthesize 1 molecule of an
amino acid or a fatty acid like palmitate.

For this reason, the bulk of glucose

catabolism in proliferating cells cannot be solely committed for ATP production. If
this were the case, the resulting rise in ATP/ADP ratio would ultimately decrease
the flux of glucose into the glycolytic pathway and the production of key glycolytic
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intermediates needed for the production of other biomolecules by the proliferating
cells would be severely impaired.
Thus, it is clear that some of the glucose has to be diverted for the formation of
macromolecular precursors such as acetyl-GoA needed for fatty acid synthesis.
For example, during fatty acid synthesis, glucose is converted to acetyl-GoA
which is then used to synthesize citrate in the TGA in the mitochondria. The
citrate molecule is then transported back into the cytosol where the acetyl-GoA is
recaptured and used to add 2 carbons to the growing fatty acid chain. This
reaction occurs under conditions of high ATP/ADP ratio such as found in
proliferating cells. For such reasons, during proliferation, the metabolism of
glucose is tightly controlled and orchestrated to support the production of key
metabolic intermediates needed for biomolecular synthesis. This control is
achieved through growth factor signaling which regulates the activity of glycolytic
enzymes such as pyruvate kinase and modulates flux of carbon through the later
steps of glycolysis [139]. For example, signaling through the PI3K pathway is
linked to protein synthesis and glucose uptake and utilization. PI3K signaling
through Akt can regulate expression of glucose transporter, and has been shown
to have direct effects on enzymes such as hexokinase and phosphofructokinase
activity [140-142]. Small molecule inhibitors that inhibit PI3K signaling also lead
to inhibition of glucose uptake and utilization and proliferation [143]. The process
of inhibition growth factor signaling has been the principal mechanism employed
to interrupt aberrant proliferation of cells under disease states.
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In the VSMCs, PDGF signals through the PI3K pathway to increase flux in
glycolysis and induce proliferation [144]. This increase in glycolytic flux caused
by PDGF depends on enhanced glucose uptake because when glucose in the
media was replaced with 2-deoxyglucose, glycolysis and proliferation were
inhibited [145]. These and several studies have thus focused on the inhibition of
PDGF signaling and glucose utilization in order to inhibit VSMC proliferation.
PDGF-induced glycolysis has been shown to provide substrates to the
mitochondria, increasing basal oxygen consumption while also enhancing
mitochondria reserve capacity [145]. The induction of proliferation by PDGF was
found not only to be dependent on increased glycolytic flux, but also on
increased LDH activity because LDH expression was increased and because Llactate could support PDGF-induced proliferation in the absence of glucose
[145]. These findings thus suggest that integrated coordination of glycolysis and
mitochondrial metabolism is required for PDGF induced proliferation, although
very few studies have interrogated the role of the mitochondria after PDGF
stimulation with respect to proliferation. Also, since phenotype switching induced
by PDGF is an energy expending process, it is of interest to determine the role
glucose metabolism plays during phenotype switching. How mitochondrial
metabolism and dynamics integrates with phenotype switching and proliferation
after PDGF stimulation warrants our attention.
Thus, the work presented was undertaken to: 1) Determine the role of autophagy
in phenotype switching induced by PDGF; 2) Determine the role of glucose
metabolism in PDGF-induced phenotype switching and proliferation; and 3) To
24

test whether changes in mitochondria dynamics regulates VSMC phenotype
switching and proliferation.

25

PROJECT OBJECTIVE

The goal of my research is to better understand the mechanisms that regulate
the VSMC phenotype in the context of vascular disease.

I hypothesize that

controlled and synchronized changes in metabolism influence or coordinate
cellular programs to elicit changes in SMC structure and function. Specifically, I
posit that changes in cell function, such as those occurring during the contractileto-synthetic phenotype

switch,

require

activation

of protein

degradation

programs, such as autophagy, to remove contractile proteins and to re-structure
the cell to perform specialized secretory functions. Specific aims to address the
aforementioned hypothesis were 1) To examine protein degradation pathways
involved during phenotype switching; 2) To determine the role of glucose
metabolism with respect to phenotype switching and 3) To examine the role of
mitochondria remodeling and substrate usage during phenotypic switching. A
significant portion of my research was directed toward understanding the role of
protein degradation mechanisms involved in growth factor-induced phenotype
conversion (Chapter II). These studies have elucidated an exciting new role of
autophagy in the regulation of the VSMC phenotype by showing that PDGF
activates a unique type of autophagy that regulates the abundance of contractile
proteins.
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Our studies

have

also

addressed

the

role

of metabolism

in

VSMC

hyperproliferative responses, such as occurs in injured vessels, where alterations
in pathways of intermediary metabolism may impact the proliferation of VSMCs
upon stimulation with growth factors.

As described in Chapter III, my studies

identify a key role for glucose metabolism pathways in the regulation of the
synthetic protein osteopontin.

Furthermore, in Chapter IV, we found that

conversion to the synthetic phenotype is associated with mitochondrial
fragmentation and a switch to fatty acid oxidation, which appear to play critical
roles in inducing the proliferative phenotype.

Collectively, these cooperative

changes in metabolism integrate to promote the development of the synthetic
VSMC phenotype. These findings provide novel and fundamental insights that
could be important for developing therapeutic approaches to treat or prevent
vascular disease.
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CHAPTER II
PDGF-MEDIATED AUTOPHAGY REGULATES VASCULAR
SMOOTH MUSCLE CELL PHENOTYPE TRANSITION AND
RESISTANCE TO OXIDATIVE STRESS INDUCED BY HNE

Introd uction

Vascular smooth muscle cells (VSMCs) are essential regulators of vascular
function. In healthy arteries, VSMCs are located in the medial vascular layer,
where they express a repertoire of contractile proteins that help to regulate vessel
tone and blood flow [36]. During atherogenesis and arterial restenosis, VSMCs
change from a contractile phenotype to a synthetic phenotype. This promotes their
migration to the intima, increases their proliferative capacity, and promotes the
synthesis of extracellular matrix proteins [146]. These changes in VSMC
phenotype appear to be fundamental in regulating the composition and stability of
vascular lesions [147].

While several factors have been suggested to mediate VSMC phenotype
transitions, platelet-derived growth factor (PDGF) is among the most robust
phenotype-modulating

agents

and
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has

been

shown

to be a primary regulator of smooth muscle cell growth and proliferation. It has
been shown that antibodies against PDGF [148-150] or PDGF receptors [151-152],
antisense oligonucleotides to PDGF receptors [153-154], or PDGF aptamers [155]
inhibit smooth muscle accumulation in the intima after balloon injury, and VSMCs
lacking PDGFR-(3 show strikingly diminished neointimal accumulation after carotid
artery ligation [156].

Moreover, pharmacological inhibition of PDGF Signaling

reduces VSMC proliferation, migration, and occupancy in the neointima [157-159].
Hence, understanding how PDGF regulates VSMC phenotype may be essential for
developing better and more targeted strategies for preventing or ameliorating
vascular disease.

The switch from the contractile to the synthetic VSMC phenotype induced by
PDGF is initiated upon PDGF binding to surface receptors, which activate several
intracellular signaling pathways that ultimately regulate gene expression and
cellular function. These signaling pathways have been shown to result in
decreased abundance of contractile proteins and increased expression of synthetic
proteins such as osteopontin [36, 106] and vimentin [160-161]. Such structural
changes have been shown to be prerequisites for enhanced cellular proliferation of
VSMCs in culture [162]. Although multiple studies have focused on identifying the
molecular mechanisms involved in phenotype switching [36, 146], it remains
unclear how VSMCs can rapidly change from the contractile to the synthetic
phenotype.

Previous work from our laboratory has shown that autophagy is

activated in VSMCs to remove oxidatively damaged proteins [133], which can form
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large aggregates that are particularly difficult to digest. This suggested to us that
the contractile apparatus, which must be removed during cellular transition to the
synthetic phenotype, may also be degraded by autophagy and that autophagy
might be an essential regulator of VSMC viability in diseased vessels. Therefore,
we examined whether PDGF-induced transition from the contractile to the synthetic
phenotype is accompanied by an increase in autophagy and whether stimulation of
autophagy is required for phenotype switching. Our results support the notion that
autophagy is essential for the conversion of VSMC from a contractile to a synthetic
phenotype and that this increase in autophagy in synthetic cells could also function
to prevent cell death due to oxidative stress.

Experimental Procedures

Materials: Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and a-

tubulin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Osteopontin
antibody was purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA).
Recombinant FGF-1 was obtained from eBiosciences (San Diego, CA, USA).
Antibodies against GAPDH, p-AktlAkt, p-p70S6K1p70S6K, p-AMPKIAMPK and pmTOR/mTOR and LC3 were purchased from Cell Signaling (Danvers, MA, USA).
Recombinant rat PDGF was obtained from R&D Biosystems (Minneapolis, MN,
USA). HRP conjugated rabbit and mouse IgG secondary antibodies were obtained
from Cell Signaling Technologies (Danvers, MA, USA). The 3-methyladenine (3MA), epoxomicin, and bafilomycin A 1 were obtained from Sigma-Aldrich. Goat anti-

30

mouse IgG-Alexafluor 555 was obtained from Invitrogen (Grand Island, NY, USA).
Spautin-1 was obtained from Cellagen Technology (San Diego, CA, USA). Ad-GFP
and Ad-GFP-lC3 were obtained from Vector Biolabs (Philadelphia, PA, USA). All
primers used for real time PCR were designed using the primer express software
from Applied Biosystems (Carlsbad, CA, USA) and then ordered from Integrated
DNA Technologies (Coralville, lA, USA). DAPI stain was obtained from Invitrogen.
Electrophoresis supplies were purchased from Bio-Rad (Hercules, CA, USA).
ECl® reagents were purchased from GE Healthcare (Pittsburgh, PA, USA).

Vascular smooth muscle cell isolation: Up to 3 extracted aortas from 6-week-

old male Sprague-Dawley rats were cleaned to remove all perivascular fat. Sterile
capel blades were used to minced aortas in a culture dish containing DMEM and
1% PIS. The minced aortas were then transferred into sterile 50ml tubes. Enzyme
solution (0.1% collagenase type 1A, 0.05% elastase type III, 2mg/ml BSA, and
2mM calcium chloride) made in DMEM containing 1% PIS was then added to the
minced aortas and incubated for 1h (at 37°C containing 5% CO 2). The enzyme
solution was mixed regularly during incubation. After digestion, supernatant was
carefully removed and discarded. Chunks of tissues at the bottom of the tube were
transferred into a new sterile tube and 5ml of fresh enzyme solution added and
digestion carried out for about 3 h while monitoring degradation of tissue. Growth
media (5 ml) was added immediately after all tissue was degraded and the entire
content centrifuged for 5 min at 1100 rpm at 4°C to pellet cells. After centrifugation,
supernatant was discarded followed by addition of more growth medium and
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another round

of centrifugation.

After the

2nd

centrifugation,

cells

were

resuspended in growth media, counted and plated at a density of 0.4-0.6x1 06 cells
per 25cm 2 flask containing 2.5 ml DMEM + 10%FBS + 1%P/S. Cells were split
when 75% confluency was achieved.

Cell culture: Isolated VSMCs were grown in DMEM (Dulbecco's modified Eagle's
medium; Life Technologies-Invitrogen) supplemented with 10% (v/v) FBS (fetal
bovine

serum;

Atlanta

Biologicals,

Atlanta,

GA,

USA)

and

0.1 %

streptomycin/penicillin. Only cells that stained positive for calponin and a-SMA
were used in experiments. To ensure maintenance of the contractile phenotype,
only cells between passages 2-7 were used. Cells were maintained in a humidified
atmosphere of air and 5% CO2 at 37 cC. At -70% confluency, VSMCs were serumstarved in DMEM containing 0.1 % FBS for 24 h. After desired treatments, cells
were rinsed twice with phosphate-buffered saline and then lysed in a protein lysis
buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1 % SDS, 1% NP40, and 1X protease and phosphatase inhibitors. The Lowry DC assay (Biorad,
City, St., USA) was used for measuring protein concentration of crude cell extracts.

Messenger RNA isolation and real-time PCR: Messenger RNA was isolated
from RASMCs using TRIZOL reagent (Invitrogen) and the concentration was
determined

by

measuring

absorbance

at

260nm

using

a

Nanodrop

spectrophotometer (Thermo scientific). A 20 IJI reverse transcription reaction
mixture containing 1 IJg mRNA, 10 units AMV reverse transcriptase, 0.4 IJM poly T
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primer (dT18), 0.2 mM dNTPs, and 20 units RNasin (Promega) was subjected to
complimentary DNA (cDNA) synthesis in a thermal cycler (BioRad).

Two

microliters of cDNA was then used for amplification of the gene of interest by real
time PCR using SYBR green (VWR, Radnor, PA, USA).

Western blotting: Approximately 0.5-25 I-Ig of crude cell protein was applied to
each lane of a 10.5-14% Bis-Tris-HCI gel and electroblotted onto a PVDF
membrane. The membrane was then incubated overnight at 4°C using appropriate
dilutions of primary antibodies. PVDF membranes were then incubated at room
temperature

with

horseradish

peroxidase-conjugated

secondary antibodies.

Immunoreactive bands were detected using a typhoon scanner (SA Biosciences,
Valencia, CA, USA) after exposure to ECl detection reagent. Bands intensity was
quantified by using the Totallab Tl120 software.

Measurement of protein-bound HNE: VSMCs were serum-starved for 24 hand
then treated without or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells
were exposed to 50 I-IM HNE in HBSS for 30 min and then replaced with 10%
FBS/DMEM. Cells were then harvested or left in the incubator for a further 3.5 h.
Cells were lysed using lysis buffer and 25 I-Ig used for Western blot to quantify
protein-HNE adducts using an anti-protein HNE antibody [133].

LDH activity assay: VSMCs were serum starved for 24h and then treated without
or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells were exposed to 50
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IJM HNE in HBSS for 30 min and then replaced with 10% FBS/DMEM media. After
16 h, the medium was collected and Iysates were prepared by scraping cells in 100

pi

of

PBS

containing

0.1 %

Triton

X-100.

LDH

activity

was

measured

spectrophotometrically for 4 min at 37°C by monitoring decrease in NADH
absorbance at 340 nm. Cytotoxicity was then estimated by dividing the change in
absorbance of the medium by the values for combined LDH activity in the medium
and the lysate as follows; cytotoxicity = [(Abs 34o media * dilution factor) I (Abs34o
Media

*

dilution factor) + (Abs lysate

*

dilution factor)]

*

100. The values were then

normalized relative to the control, which represented 100% cell viability [163].

Adeno-viral gene fransfecfion: VSMCs were serum starved for 24 h and then
infected with replication-deficient adenoviruses carrying either GFP (AdGFP) or
GFP fused LC3 (AdGFP-LC3). Adenoviruses were used at a multiplicity of infection
(MOl) of 100 and GFP expression was used to ascertain transfection efficiency.
AdGFP or AdGFP-LC3 transfected cells were then stimulated with PDGF at the
indicated times. Before imaging, cells were incubated with Hoechst stain for
nuclear visualization.

Immunofluorescence confocal imaging: VSMCs were washed with PBS and
then fixed in ice-cold (-20 DC) methanol for 5 min. The cells were then incubated
for 30 min at room temperature (RT) in a blocking solution (5% BSA in PBS)
followed by incubation for 1 h with a 1:500 dilution of anti-a-sm-actin primary
antibody at room temperature. A 1: 1ODD-diluted solution of goat anti-mouse IgG
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Alexa555 secondary antibody was used for incubation after treatment with the
primary antibody. After three washes with PBS, the cells were counterstained with
DAPI for 10 min at RT. The cells were then mounted on glass slides using the
mounting medium and cover slips were added. a-SMA staining was visualized
using a NIKON A 1 confocal microscope. Cells plated on glass-bottom dishes were
transfected with adenoviruses as described above. After loading with each dye, the
cells were placed in phenol red-free DMEM supplemented with 25 mmol/L HEPES
(pH 7.4). The cells were illuminated (488- and 568-nm lines of a krypton/argon
laser), and images were acquired.

Transmission electron microscopy: VSMCs were grown on cover slips (Ladd
Research, Williston, VT, U.S.A.), serum-starved for 24 h, and then treated with
PDGF (20 ng/ml) for 48 h. Control cells were left untreated. After treatment, cells
were washed with PBS and fixed with 3% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4) for 2 h at room temperature (25°C). The cells were
then post-fixed with 1% osmium tetroxide, sectioned and embedded in LX112
plastic. Ultrathin sections were stained with uranyl acetate and lead citrate, and
electron micrographs were taken using a PhilipsCM10 transmission electron
microscope operating at 60 kV (x1 000- 72000 magnification) [133].

Statistical analysis: Data are mean ± SEM. Multiple groups were compared using
one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's t test was
used for direct comparisons. A p value <0.05 was considered significant.
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Results

Platelet derived growth factor induces phenotype switching in VSMCs: To
examine the mechanisms regulating the phenotypic transition of VSMCs, we first
measured changes in molecular markers of contractile and synthetic VSMC
phenotypes. For this, VSMCs were deprived of serum for 24 h to induce cell cycle
arrest. The cells were then incubated with vehicle or PDGF-BB (20 ng/ml) for 24
and 48 h. Relative mRNA and protein abundance was measured by RT-PCR and
Western blotting, respectively.

As shown in Fig. 1A, PDGF treatment for 24 h

resulted in a - 50% decreases in the mRNA levels of a-sm-actin and calponin and
a robust upregulation of osteopontin (12-fold) and vimentin (2-fold). After 48 h, the
levels of a-SMA protein were decreased by 25%, calponin abundance was
decreased by 75%, and osteopontin protein was elevated 2-fold (Figure 1Band
1C).

Immunofluorescence

imaging

of

a-SMA

filaments

showed

marked

disorganization in PDGF-treated cells compared with control cells 48 h after PDGF
treatment (Figure 1D).

These results confirm previous findings [36, 50, 162]

showing that PDGF promotes phenotypic transition of VSMCs.

PDGF induces autophagy in VSMCs: The relatively rapid loss of contractile
proteins suggested to us that proteolytic mechanisms may function to remove the
contractile apparatus to aid in the transition from the contractile to the synthetic
phenotype.

Indeed, previous studies have shown that proteasome and calpain
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inhibitors affect VSMC phenotype [164-166]; however, these studies showed that
proteasome inhibition counter intuitively decreases markers of the contractile
phenotype [165] resulting in reduced cell contractility[166].

Therefore, we

hypothesized that autophagy may be important for the removal of contractile
proteins and protein complexes.

To test this hypothesis, we first assessed the

effects of PDGF on autophagy in VSMCs by examining LC3-11 formation-an
indicator of autophagy [167-168].

As shown in Fig. 2A-C, PDGF stimulation

caused a time-dependent increase in LC3-11 formation. A significant increase in
LC3-11 was observed 12 h after PDGF stimulation and maximal increases in LC3-11
were obtained 48 h after PDGF treatment, suggesting that stimulation with PDGF
increases autophagy.
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Figure 1. PDGF induces a contractile-to-synthetic phenotype switch in
VSMCs. Indices of vascular smooth muscle cell phenotype: A) Quantitative

real-time PCR following PDGF-BB (20 ng/ml) stimulation for 24 h. Calponin,
a-sm-actin and MHC II are markers of the contractile phenotype, osteopontin
and vimentin are associated with a synthetic phenotype. *p<0.05 vs control,
n=3 per group. B) Western analysis of contractile and synthetic proteins after
PDGF stimulation: VSMCs were serum-starved for 24 h and then stimulated
with PDGF for 48 hand 0.5-2 IJg protein was used for immunoblot analysis.
C) Quantification of immunoblots from panel B (n=3 per group, *p<0.05 vs

control). D) Confocal images of a-sm-actin (red) distribution in VSMCs
treated without and with PDGF (20 ng/ml) for 48 h. Blue staining indicates
nuclear staining with DAPI (Scale bar = 20 IJm).
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Because the formation of LC3-11 is transient and the protein is rapidly degraded in
the lysosome, an increase in LC3-11 could also paradoxically indicate a decrease in
autophagy. Hence, to determine total LC3-11 formation, we inhibited its lysosomal
degradation by treating cells with bafilomycin A 1, which inhibits vacuolar-type H+ATPase [168-169]. As shown in Fig. 2D-F, treatment of PDGF-stimulated cells with
bafilomycin led to a greater increase in LC3-11 abundance than was observed in
untreated cells, indicating a net increase in LC3-11 formation and upregulation of
autophagic machinery in PDGF-treated cells (Fig. 2D-F). These effects appear to
be specific to PDGF because treatment with fibroblast growth factor 1 (FGF-1), a
known VSMC mitogen [170], did not affect the abundance of contractile proteins or
increase LC3-11 formation, despite increasing cell proliferation to levels similar to
that of PDGF (Fig. 2G-J).

To obtain further evidence for the induction of

autophagy by PDGF, we transduced VSMCs with a GFP-LC3 adenovirus and
assessed the formation of punctate LC3, which is indicative of its autophagosomal
localization [168].

As shown in Fig. 3A-B, there was a 2-fold increase in

fluorescent puncta in PDGF-treated cells, and this was further increased by
bafilomycin A 1 treatment.

PDGF induces ultrastructural changes and extensive vacuolization in
VSMCs: Although LC3-11 formation is a validated marker of autophagy, changes in

the ultrastructure showing the formation of autophagosomes is considered the
"gold-standard" for documenting autophagy.

Hence, to examine ultrastructural

changes, VSMCs were treated with PDGF for 48 h and then visualized by
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transmission electron microscopy. Transmission electron micrographs of these
cells showed that treatment with PDGF (20 ng/ml) for 48 h caused a -3 fold
increase in autophagosomes (indicated with red arrows, Fig. 3D, E) when
compared with untreated cells (Fig. 3C). In addition, PDGF treatment resulted in
extensive vacuolization and consistent formation of a singular, large phagosome
per cell, which may serve as a designated compartment for the digestion of
intracellular materials. Collectively, these structural changes are in concordance
with our immunological and fluorescence-imaging data and suggest that PDGF is a
robust inducer of the autophagic program.
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Figure 2. PDGF-BB induces autophagy in VSMCs. Quantification of LC3
abundance and localization to puncta: A) Immunoblot analysis of LC3. After 24 h of
serum deprivation, VSMCs were stimulated with PDGF for 24 h and abundance of
LC3 was detected by Western blotting; B, C) Quantification of LC3 from panel A.
*p<0.05 vs control group, n = 3 per group; D) Measurements of autophagic flux:
Bafilomycin A 1 (2 !-1M) was added to control or PDGF-stimulated cells 4 h prior to
harvest. Accumulation of LC3-11 was measured by Western blotting; E, F)
Quantification of LC3 from panel D. *p<0.05 vs. the indicated group, n=3 per
group. (n=3 per group, #p<0.05 vs baf or vs PDGF+baf, *p<0.05 vs Ctrl); and G-J)
Effects of FGF-1 on proliferation, contractile protein abundance, and autophagic
flux in VSMCs: panel J, comparison of VSMC proliferation when treated with FGF1 (25 ng/ml) and PDGF-BB (25 ng/ml) for the indicated time. Cells were counted at
the end of the treatment period using a hemocytometer. Panel H, representative
western blots of contractile proteins in cells treated with FGF-1 (0-50 ng/ml); Panel
I, representative western blot of autophagic flux in untreated and FGF-1-treated
cells. Note that bafilomycin (2 !-1M) was added 4 h prior to harvesting cells. Panel
J, densitometry measurements of LC3 from panel H. *p<0.05 vs. control group, n =
3 per group.
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PDGF-induced autophagy is required for phenotype switching: To examine
whether autophagy plays a role in VSMC phenotype switching, we pretreated
VSMCs with the pharmacological inhibitor of autophagy, 3-methyladenine (3MA)[171], prior to stimulating the cells with PDGF. As shown in Fig. 4A and B, 3MA decreased GFP-LC3 puncta formation by 50%. This inhibition of autophagy
was associated with partial stabilization of the contractile markers calponin and aSMA (Fig. 4A-D) and inhibition of smooth muscle cell proliferation (Fig. 4E).
Because of potential, off-target effects of 3-MA [172-174] and the relatively high
concentrations of the compound needed to inhibit the autophagic machinery, we
tested whether spautin-1, a more specific inhibitor of autophagy, would affect
VSMC phenotype. Spautin-1 has been recently shown to prevent autophagy by
inhibiting the deubiquitinases USP10 and USP13, which leads to beclin 1
degradation (Fig. 5A) [175].

Pretreatment of VSMCs with spautin-1 (10 IJM)

prevented PDGF-induced disorganization of actin filaments (Fig. 5B). Western blot
analysis demonstrated that inhibition of autophagy with spautin-1 prevented
increases in LC3-11 and losses of calponin and a-SMA after PDGF exposure (Fig.
5C-F). Spautin treatment also prevented VSMC hyperproliferation (Fig. 5G).
To determine if the proteasome plays a role in regulating VSMC phenotype
switching, we treated cells with the proteasome inhibitor epoxomicin [176] prior to
PDGF treatment and examined contractile protein expression.

Although

epoxomicin treatment inhibited proteasomal activity, as evidence by the increased
abundance of ubiquitinated proteins (Fig. 6A, B), the loss of contractile proteins
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due to POGF treatment remained largely unaffected (Fig. 6C-E).

Collectively,

these results suggest that autophagy, and not proteasomal activity, is required for
phenotypic changes in POGF-stimulated VSMCs.

Synthetic VSMCs are resistant to aldehyde-induced cell death: Lesions in
atherosclerotic and restenotic vessels are characterized by increased amounts of
proteins modified by lipid peroxidation products such as 4-hydroxy-trans-2-nonenal
(4-HNE) [177-178]. Because previous findings suggest that autophagy prevents
toxicity due to 4-HNE [133], we hypothesized that synthetic VSMCs having higher
autophagic flux might be protected from 4-HNE-induced cell death. This could be
important because synthetic VSMCs are the abundant phenotype found in vascular
lesions; hence, their survival may be impacted by their ability to handle oxidative
insults. Indeed, as shown in Fig. 7A, cell viability of synthetic VSMCs challenged
with HNE was significantly enhanced compared with HNE-challenged contractile
VSMCs (p<O.05).

Consistent with the role of autophagy in clearing oxidatively

damaged proteins [133, 179], synthetic VSMCs resisted accumulation of proteinHNE adducts due to exogenous HNE exposure (Fig. 7B and C). Inhibiting
autophagy with spautin-1 promoted accumulation of HNE-damaged proteins (Fig.
70 and E). These results suggest that POGF-induced autophagy may be important
for promoting the survival of VSMCs found in diseased vessels.
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Figure 3.

PDGF-BB increases autophagosome formation and promotes

extensive vacuolization. Microscopic evaluation of autophagy and VSMC
ultrastructure: A) Representative confocal images of VSMCs transfected with AdGFP (i and ii) or Ad-GFP-LC3 (iii, iv, v, and iv) treated without or with PDGF and/or
bafilomycin; B) Quantification of puncta in panel B (> 20 cells counted per field in
each group, *p<0.01 vs. the indicated groups; C-E) Representative transmission
electron micrographs of cells treated with vehicle (panel C) or PDGF (panel D) for
48 h. E) Magnified image of boxed area in panel B. Double membrane-bound
structures identified as autophagosomes in panels D and E are indicated by the
red arrows. N=nucleus, M=mitochondria, V=vacuoles. Magnification = x7100 F)
Quantification of autophagosomes in images from control and PDGF treatment
groups. *p<0.05 vs control.
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Discussion

The present study demonstrates autophagy as a novel mechanism regulating
VSMC phenotype. We found that PDGF, which promotes the development of the
synthetic VSMC phenotype,

is a robust inducer of autophagy and that

pharmacological inhibition by two structurally-unrelated inhibitors of autophagy
blocked

the

degradation

of

calponin

and

a-sm-actin

and

prevented

hyperproliferation and the transition to the synthetic phenotype. We also found
that the synthetic phenotype was more resistant to the electrophilic stress
commonly encountered in diseased vessels, and this was associated with an
increased ability to remove proteins damaged or modified by electrophiles. These
findings uncover PDGF-mediated autophagy as an important regulator of VSMC
phenotype.

Previous studies have identified numerous factors that regulate phenotype
plasticity in VSMCs. For example, contractile agonists, reactive oxygen species
and extracellular matrix components have been shown to regulate the expression
of contractile genes [53-54, 180-184]. Conversely, growth factors such as PDGF
and oxidized phospholipids are known to favor the synthetic phenotype [50, 61, 66,
185]. Several studies have elucidated molecular mechanisms governing the switch
to the synthetic phenotype. The signaling pathways known to trigger the synthetic
phenotype culminate in the displacement of myocardin, a coactivator of serum
response factor, from the consensus CArG box upstream of smooth muscle cell
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marker genes [186]. PDGF is known to act through transcription factors such as
KLF4 and Elk-1 as well as microRNAs (such as miR221 and miR222) leading to
the displacement of myocardin and downregulation of VSMC contractile genes [92,
124, 187-188]. Hence, most studies to date examined transcriptional and
translational changes regulating phenotypic transition; few,

however, have

explored post-transcriptional and -translational mechanisms.

We posited that one limiting event to transition to the synthetic phenotype would be
removal of the contractile apparatus. Degradation of contractile proteins would
likely involve the proteasome, autophagy, or both. Interestingly, the proteasome
has been shown to playa role in VSMC hyperplasia but not phenotype switching
[130, 189]; and paradoxically, inhibitors of the proteasome decrease markers of the
contractile phenotype [165] resulting in reduced cell contractility [166].

In our

studies, we found that inhibition of the proteasome with epoxomicin had little effect
on contractile protein abundance, suggesting to us that autophagy could be the
major proteolytic device employed by the cell to remove contractile proteins.

We found that PDGF induced a robust form of autophagy characterized by
increased LC3-11 abundance, augmented autophagic flux, and the formation of
autophagosomes and vacuoles.

The induction of autophagy was specific to

PDGF: the mitogen FGF, while increasing proliferation to a similar extent as
PDGF, did not induce autophagy. While factors such as TNF-a and osteopontin
have been shown to promote autophagy in VSMCs [109, 190], there are
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surprisingly few reports of induction of autophagy by growth factors. In fibroblasts
and cancer cells, connective tissue growth factor (CTGF) has been shown to
activate autophagy and regulate proliferation [191], and transforming growth factor~ (TGF-~)

activates autophagy in hepatocellular carcinoma cells [192].

In these

cases, the induction of autophagy is usually associated with diminished
proliferation; however, we found that autophagy may be important for PDGFmediated hyperproliferation, as inhibition of autophagy with 3-MA or spautin-1
prevented cellular proliferation induced by PDGF. We hypothesize that this may
be due either to stabilization of contractile proteins, which might structurally hinder
cell division, or to decreased generation of metabolic building blocks, e.g., amino
acids, which would be a natural consequence of enhanced autophagic activity and
could be used to supply energy requirements for increased proliferation.

It remains unclear why rapamycin, which is an inhibitor of mTOR and activator of
autophagy, promotes the contractile phenotype in VSMCs [83, 193] while PDGFmediated autophagy induces the synthetic phenotype.

It is likely that the form of

autophagy induced by PDGF is uniquely poised to degrade contractile proteins and
is tailored to regulate the phenotype switch.

In addition to contractile proteins, autophagy has been shown to be important in
preventing accumulation of damaged or aggregated proteins [133, 179, 194]. We
found that the increase in autophagic flux in PDGF-treated VSMCs was sufficient
to decrease cell death and the abundance of protein-HNE adducts after an
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aldehyde challenge, suggesting that synthetic VSMCs may be better able to
tolerate the high levels of oxidant stress occurring in vascular lesions. This may be
an important feature of synthetic cells, as it may regulate the survival of VSMCs in
the fibrous cap, which, at least in part, is responsible for maintaining plaque
stability [195]. Interestingly, the form of autophagy induced by PDGF appears to be
functionally different from what has been described to occur with other stimuli. For
example, TNF-a and IGF-1 were shown to increase autophagy in VSMCs, yet
promote an autophagic form of cell death [190]. That PDGF promotes autophagy,
cell survival, and increases the formation of extracellular matrix therefore suggests
that it safeguards plaque-resident VSMCs against oxidative injury while potentially
increasing the stability of lipid-laden atherosclerotic plaques.

Although the non-specific effects of pharmacological inhibitors cannot be rigorously
ruled out, our observation that two structurally different inhibitors that target
different components of the autophagic machinery were effective at stabilizing
calponin and a-SMA support the view that autophagy is required for PDGFinduced phenotype conversion.

Nevertheless, spautin was more robust in

stabilizing the contractile VSMC phenotype, and it completely prevented the
hyperproliferation of VSMCs after PDGF exposure. The inhibition of autophagy
with spautin did not affect PDGF signaling through Akt and Erk, further suggesting
that inhibition of phenotype switching was due to stabilization of the contractile
apparatus (Figure 8). These results suggest that spautin might be a useful

51

therapeutic agent for preventing abnormal proliferation of smooth muscle cells in
vascular injury or restenosis.

In summary, the present study identifies a new mechanism by which autophagy is
activated and shows that autophagy is critical for attaining a synthetic VSMC
phenotype and for increasing resistance to oxidative stress. Our observations also
suggest that therapies targeting autophagy might be useful in preventing aberrant
smooth muscle cell growth, but that such interventions may have deleterious
effects on synthetic smooth muscle cell survival under conditions of oxidative
stress. Future studies are required to identify the detailed molecular mechanism(s)
by which PDGF activates the autophagic program and to test how modulating
PDGF-mediated autophagy affects the progression of vascular disease.
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Figure 4. Inhibition of autophagy prevents PDGF-induced phenotype
switching. Measurements of autophagy and contractile phenotype in cells treated
with autophagy inhibitors: A) Representative confocal images of VSMCs treated
with PDGF in the absence or presence of 3-MA (10 mM). B) Quantification of
fluorescent puncta from panel A. *p<0.03, n=10 per group. C) Western analysis of
contractile protein expression. VSMCs were serum-starved for 24 h and then
stimulated with PDGF (20 ng/ml) for 48 hours. 3-MA (10 mM) was added 30 min
prior to PDGF stimulation. D-E) Quantification of immunoblots represented in panel
C. F) Cell proliferation in VSMCs: VSMCs were treated with vehicle or PDGF in the
absence or presence of 3-MA. After 48 h, the cells were trypsinized and counted
using a hemocytometer.

*p<0.05 vs. PDGF only and #p<0.05 vs non-PDGF-

treated cells, n=3 per group.
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Figure 5. Spautin 1, an inhibitor of autophagy, prevents PDGF-induced
phenotype switching. A) Mechanism of action of spautin 1: Spautin 1 promotes
the

degradation

deubiquitinases;

of beclin

1 through

inhibition

of

USP10

and

USP13

B) Representative confocal images VSMCs treated without or

with PDGF in the absence or presence of spautin 1 (10 !-1M). Scale bar = 10 !-1m. C)
Representative Western blots of LC3 and contractile proteins. D-F) Quantification
of immunoblots from panel C. G) Cell proliferation in VSMCs: VSMCs were treated
with vehicle or PDGF in the absence or presence of spautin-1. After 48 h, the cells
were trypsinized and counted using a hemocytometer. *p<O.05 vs. CTRL; #p<O.05
vs. PDGF group, n=3 per group.
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Figure 6. Inhibition of the proteasomal pathway does not inhibit PDGFinduced contractile protein degradation. Immunoblot analysis of ubiquitinated
proteins and contractile proteins: A) Accumulation of ubiquitinated proteins after
epoxomicin (100 nM) treatment; B) Quantification of A (n=3 per group, *p<0.05 vs
control). C-E) Effects of epoxomicin on calponin and a-sm-actin degradation. C}
Representative western blots. D-E} quantification of C (n=3 per group, *p<0.05 vs
PDGF).
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Figure 7. Synthetic VSMCs are resistant to HNE-induced toxicity.

A) Cell

viability in HNE-treated cells: VSMCs were treated with vehicle or PDGF for 48 h
and then exposed to HNE (50 !-1M) for 30 min in HBSS.

The HNE-containing

medium was removed and replaced with growth medium, and cell viability was
assessed by LDH assay 16 h later. *p<0.05 vs. HNE, &p<0.05 vs CTRL, n=3 per
group. 8, C) Protein-HNE adduct formation in contractile (control) and synthetic
(PDGF-treated) cells: The cells were treated with HNE (50 !-1M) for 30 min in
HBSS. The medium was then replaced with growth medium and the cells were
harvested after 3.5 h for examination of HNE adducts.

Representative protein-

HNE blots are shown in panel B and quantification is shown in panel C. *p<0.005
vs HNE, n=3 per treatment group. 0) Representative immunoblots of protein-HNE
adducts in contractile and synthetic VSMCs treated without (left panel) or with
spautin-1 (right panel). E)

Quantification of groups shown in panel D. All

densitometric measurements were normalized to a-tubulin. *p<0.05, n=3 per
group.
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Figure 8. Spautin 1 does not interfere with PDGF-induced Akt or Erk1/2
signaling. A) Western blot analysis of Akt and Erk1/2 phosphorylation status:
VSMCs were pretreated with spautin-1 for 30 min before PDGF stimulation at the
indicated times. B, C) Quantification of A (n=3, *p<0.05 vs 0 min).
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CHAPTER III

REGULATION OF VASCULAR SMOOTH MUSCLE CELL
PROLIFERATION AND PHENOTYPE SWITCHING BY O-GlcNAc
Introduction

Glucose metabolism in VSMCs occurs via four major pathways: the glycolytic,
the polyol, the hexosamine biosynthetic, and the pentose phosphate pathways.
These pathways have been shown to regulate VSMC hyperplasia and function.
For example, inhibition of aldose reductase, the rate-limiting enzyme in the polyol
pathway, prevents VSMC proliferation induced by the cytokine TNF-a [196];
increased flux into the hexosamine biosynthetic pathway (HBP) has been shown
to inhibit VSMC proliferation and reduce neointima formation after balloon injury
[197]; increased glycolytic flux promotes PDGF-induced VSMC hyperplasia [198];
and, glucose-6-dehydrogenase (G6PD), the rate-limiting enzyme in the pentose
phosphate pathway, has been shown to regulate VSMC contractility [199]. Thus,
glucose metabolism is an important aspect of vascular complications involving
the VSMC. Despite such findings, vascular proliferative diseases such as
atherosclerosis continue to be major causes of death [200]. Therefore further
understanding of glucose metabolism in the VSMC is needed to expose new
avenues for clinical intervention.
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VSMC hyperproliferation is mediated by growth factors and environmental cues.
Platelet derived growth factor BB (PDGF-BB or PDGF) is the most potent inducer
of VSMC proliferation and it is released from platelets, macrophages, and
endothelial cells during vessel injury [36]. PDGF stimulation of VSMCs causes
increased secretion of cytokines, particularly osteopontin, a pro-proliferative
cytokine which is important for VSMC migration and extracellular matrix
formation during atherogenesis and restenosis [103]. The levels of osteopontin
expression are regulated by transcription factors which are under the influence of
cellular glucose levels [201]. This suggests that regulating glucose metabolism
(or cellular glucose concentrations) could be important in regulating VSMC
osteopontin expression and VSMC proliferation. In particular, the mechanisms by
which glucose metabolism regulate osteopontin expression are unclear and how
accessory pathways, such as the HBP, affect OPN expression and VSMC
phenotype are understudied.
The hexosamine biosynthetic pathway (HBP) utilizes about 2-5% of glucose in
mammalian cells [202], and this pathway has been implicated in VSMC
neotintimal formation during vascular remodeling [203]. The enzyme, Lglutamine-D-fructose 6-phosphate amidotransferase (GFAT) is the regulatory
enzyme mediating glucose flux into the HBP [204]. GFAT converts fructose-6phosphate to glucosamine-6-phosphate which, through a series of reactions is
subsequently converted to uridine diphosphate N-acetylglucosamine (UDPGlcNAc). UDP-GlcNAc is then used as a donor for the formation of O-linked-Nacetylglucosamine (O-GlcNAc) modified proteins as well as other proteoglycans,
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glycosamino glycans, and glycolipids [205]. O-GlcNAc modification regulates
several biological processes such as apoptosis, signal transduction, transcription,
translation, nuclear transport and protein degradation [206-213]. O-GlcNAcylation
is also important in diseases such as cancer, diabetes and Alzheimer's disease
[214-217].

To

date,

two

key

enzymes which

perform

kinase-like

and

phosphatase-like activities with respect to protein O-GlcNAc modification have
been described: O-GlcNAc transferase (OGT) catalyses the transfer of the
GlcNAc (I3-N-acetylglucosamine)

moiety from

UDP-GlcNAc to conserved

serine/threonine residues of protein via an O-linkage [218]. Proteins which have
been O-GlcNAc modified are converted back to their unmodified form through the
action of O-GlcNAcase which removes the GlcNAc moiety to form UDP-GlcNAc
[219]. Flux into the HBP controls levels of O-GlcNAcylated proteins, and OGT is
very sensitive to levels of cellular UDP-GlcNAc [220]. In 1998, Nerlich et al [221]
found an increase in GFAT expression under hyperglycemic conditions thereby
suggesting a role of the HBP in diabetic vascular complications. Akimoto et al
[222] later showed that high glucose caused elevated OGT expression leading to
alteration of protein O-GlcNAc patterns. These studies suggest that the increase
in VSMC hyperplasia observed under hyperglycemia is attributable to increased
in glucose flux into the HBP. However, several studies have shown the contrary,
for example, Slawson et al [223] showed that increasing levels of protein 0GlcNAc modification using pharmacological inhibitors such as PUGNAc (which
inhibits O-GlcNAcase) or through adenoviral gene over expression of OGT led to
altered expression of cyclins and defects in mitotic progression. Subsequently,
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Xing et al [203] showed that increasing protein O-GlcNAc by glucosamine or
PUGNAc treatment inhibited neointima formation after balloon injury of the rat
carotid artery. This inhibition, Xing and colleagues suggest, was due to inhibition
of cytokine expression after injury. However, the direct role of the HBP and 0GlcNAc protein modification on VSMC phenotype has not been assessed.
Therefore, studies addressing the effects of glucose metabolic pathways such as
glycolysis and the HBP on phenotype switching and hyperproliferation are
needed.
In this study, we determined the effects of the GAPDH inhibitor, koningic acid
(KA), and the O-GlcNAcase inhibitor, thiamet-g on PDGF-induced VSMC
proliferation. These inhibitors have been demonstrated to be specific to their
respective targets at low concentrations while producing minimal or no side
effects [224-225]. Both KA and thiamet-g prevented PDGF-induced VSMC
proliferation. KA inhibited glucose flux to glycolysis and inhibited osteopontin
expression. These effects of KA resulted in inhibition of PDGF-induced
proliferation. KA treatment led to a small but significant increase in levels of
protein O-GlcNAc formation thereby suggesting an antiproliferative role of the
HBP. Indeed, Thiamet-g treatment, which caused increased protein O-GlcNAc
formation, inhibited PDGF-induced osteopontin expression, and stalled the cells
in the S-phase of the cell cycle. Expression of cell cycle proteins cyclin D1 and
PCNA were inhibited in the presence of Thiamet-g. These findings reveal the
importance of the glycolytic and the HBP pathways with respect to PDGFinduced VSMC proliferation and reveal two new inhibitors of VSMC proliferation
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that could potentially be developed for the treatment of vascular diseases such
as atherosclerosis and restenosis.

Experimental procedures

Materials: Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and
a-tubulin were purchased from Sigma-Aldrich (St. louis, MO, USA). Antibodies
against GAPDH, p-AkUAkt and p-Erk1/2/Erk1/2 were purchased from Cell
Signaling (Danvers, MA, USA). Antibodies against osteopontin, cyclin D1 and
PCNA were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA).
Antibody against protein O-GlcNAc was obtained from Covance (Princeton, NJ,
USA). Recombinant rat PDGF was obtained from R&D Biosystems (Minneapolis,
MN, USA). HRP conjugated rabbit and mouse IgG secondary antibodies were
obtained from Cell Signaling Technologies (Danvers, MA, USA). All primers used
for real time PCR were designed using the primer express software from Applied
Biosystems (Carlsbad, CA, USA) and then ordered from Integrated DNA
Technologies (Coralville, lA, USA). Electrophoresis supplies were purchased
from Bio-Rad (Hercules, CA, USA). ECl® reagents were purchased from GE
Healthcare (Pittsburgh, PA, USA). MTT reagent was obtained from Sigma Aldrich
(St. louis, MO, USA). Koningic acid was obtained from COSMO BIO CO lTD
(Carlsbad, CA, USA). Thiamet-G was obtained from Cayman Chemical (Ann
Arbor, MI, USA). The Cyquant proliferation assay kit was obtained from
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Invitrogen Life Technologies (Grand Island, NY, USA). Propidium Iodide was
purchased from eBioscince (San Diego, CA, USA).

Cell culture: Rat aortic smooth muscle cells (VSMCs) were isolated from the
aortas of 6-week-old male Sprague-Dawley rats and grown in DMEM (Dulbecco's
modified Eagle's medium; Life Technologies-Invitrogen) supplemented with 10%
(v/v) FBS (fetal bovine serum; Atlanta Biologicals, Atlanta, GA, USA) and 0.1 %
streptomycin/penicillin. To ensure maintenance of the contractile phenotype, only
cells between passages 2-7 were used. Cells were maintained in a humidified
atmosphere of air and 5% CO 2 at 37°C. At -70% confluency, VSMCs were serumstarved in DMEM containing 0.1 % FBS for 24 h. After desired treatments, cells
were rinsed twice with phosphate-buffered saline and then lysed in a protein lysis
buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1 % SDS, 1% NP40, and 1X protease and phosphatase inhibitors. The Lowry DC assay (Biorad,
City, St., USA) was used for measuring protein concentration of crude cell extracts.

Messenger RNA isolation and real-time peR: Messenger RNA was isolated
from RASMCs using TRIZOL reagent (Invitrogen) and the concentration was
determined

by

measuring

absorbance

at

260nm

using

a

Nanodrop

spectrophotometer (Thermo scientific). A 20 1-11 reverse transcription reaction
mixture containing 1 I-Ig mRNA, 10 units AMV reverse transcriptase, 0.4 I-IM poly T
primer (dT18), 0.2 mM dNTPs, and 20 units RNasin (Promega) was subjected to
complimentary DNA (cDNA) synthesis in a thermal cycler (BioRad).

Two

microliters of cDNA was then used for amplification of the gene of interest by real
time PCR using SYBR green (VWR, Radnor, PA, USA).
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Western blotting: Approximately 0.5-25 I-Ig of crude cell protein was applied to
each lane of a 10.5-14% Bis-Tris-HCI gel and electroblotted onto a PVOF
membrane. The membrane was then incubated overnight at 4°C using appropriate
dilutions of primary antibodies. PVOF membranes were then incubated at room
temperature

with

horseradish

peroxidase-conjugated

secondary

antibodies.

Immunoreactive bands were detected using a typhoon scanner (SA Biosciences,
Valencia, CA, USA) after exposure to ECl detection reagent. Bands intensity was
quantified by using the Totallab Tl120 software.
For protein O-GlcNAc Western blots: VSMCs were treated with PUGNAc or
thiamet-g, inhibitors of O-GlcNAcase, or vehicle (0.1 % ethanol) for overnight and
then treated with POGF for 48 h. Total cell lysate was prepared as described
above. After transfer of proteins onto PVOF, membrane was immediately put in
methanol for 1 min and then allowed to dry at RT for 2 h. After drying, membrane
was incubated with 1: 1000 dilution of anti-protein O-GlcNAc antibody (diluted in
PBS-casein; cat no. 161-0783, Bio-Rad, Hercules, CA, USA) for overnight.
Membrane was then washed 3x10 mins each and then incubated with appropriate
secondary antibody (diluted in PBS-casein) for 1 h at RT. After second incubation,
membrane was imaged using the Typhoon scanner.

Measurement of cellular energetics using the XF24 extracellular flux
analyser: Cellular energetics was measured in intact VSMCs using a Seahorse
Bioscience XF24 extracellular flux analyser.

Approximately 40,000 cells were

seeded in wells of a 24-well XF plate. Cells were then serum starved in 0.1 %FBS
OM EM for 24h. After serum starvation the media was replaced with phenol red
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free DMEM containing 1mM pyruvate, 5 mM glucose and 3.97mM Glutamax-I.
After equilibration in phenol red free DMEM, PDGF was then injected into cells
and their extracellular acidification rates (ECARs) measured. Oligomycin was
later injected to obtain the maximal glycolytic capacity of the cells. Koningic acid
(KA) was added to inhibit glycolysis. Data obtained were normalized to the
amount of protein present in the well of the microplate. For normalization, cells
were lysed in the 24-well XF plates using 20 pI/well of protein lysis buffer. Protein
concentration was then measured using the Lowry's method.
Cell cycle studies with propidium iodide: VSMCs were harvested after 3 min
trypSin incubation, washed with phosphate buffered saline (PBS) and cold 70%
ethanol added to the cells. VSMCs were then fixed by incubating for 1 hour at
4°C. After fixing, cells were sedimented at 500 x g for 5 mins and the supernatant
discarded. Cells were then washed again with PBS and 3001-11 RNase buffer
containing 51-11 propidium iodide added after all residual PBS has been discarded.
Cells were then mixed and incubated at room temperature for 45 mins after
which they were analyzed using a C6 Accuri flow cytometer.
Cell viability assays: VSMCs were serum starved for 24h and then treated
without or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells were
exposed to 50 I-IM HNE in HBSS for 30 min and then replaced with 10%
FBS/DMEM media. After 16 h, the medium was collected and Iysates were
prepared by scraping cells in 100 pi of PBS containing 0.1 % Triton X-100. LDH
activity was measured spectrophotometrically for 4 min at 37°C by monitoring
decrease in NADH absorbance at 340 nm. Cytotoxicity was then estimated by
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dividing the change in absorbance of the medium by the values for combined
LDH activity in the medium and the lysate as follows; cytotoxicity

= [(Abs34o

media * dilution factor) / (Abs 34o Media * dilution factor) + (Abs lysate * dilution
factor)] * 100. The values were then normalized relative to the control, which
represented 100% cell viability.
For cytotoxicity assays, after desired treatment, cells were incubated in a solution
of 0.2 mg/ml MTT reagent for 2-4h at 37°C in an incubator containing 5% CO 2 .
After incubation, MTT reagent was then aspirated and the purple crystals at the
bottom of the plate dissolved in DMSO. Absorbance at 540 nm was then
measured using a microplate reader.

Statistical analysis: Data are mean ± SEM. Multiple groups were compared using
one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's t-test was
used for direct comparisons. A p-value <0.05 was considered significant.
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Results

PDGF induces expression of osteopontin in cultured VSMCs: To determine
the effects of PDGF on glucose metabolism in isolated VSMCs, we first
measured changes in proliferation and osteopontin expression on VSMCs
isolated from rat aortas. For this, VSMCs were serum starved for 24 h in 0.1 %
FBS and then stimulated with PDGF (20ng/ml) for 24 h. Consistent with previous
findings, PDGF induced about a 2.5-fold increase in osteopontin protein
abundance, increased proliferation by 2-fold as measured by counting cell
number or measuring DNA content (Figure 9A and B). The increase in cell
proliferation was accompanied with 1.7- and 2.3-fold increases in the expression
of cell cycle regulatory proteins such as cyclin 01 and PCNA, respectively
(Figure 9C and D).
PDGF increases glycolytic flux in VSMCs: To determine the effects of PDGF
on glycolytic flux, we serum starved VSMCs for 24 h and then stimulated serum
starved cells with different concentrations of PDGF. As shown in Figure 10,
PDGF at a concentration of 25ng/ml increased basal and maximal glycolytic flux
with an insignificant increase in the glycolytic reserve capacity. Koningic acid
completely inhibited glycolytic flux in VSMCs.
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Figure 9. PDGF-BB induces VSMC proliferation and expression of
osteopontin. A and B) Measurement of cell proliferation after PDGF stimulation.
Cell proliferation measured by counting cell numbers (A) and by measurement of
cellular DNA content using the cyquant fluorescent dye (B),

n=6, *p<O.01 vs.

control. C and D) Expression of cell cycle proteins and osteopontin after PDGF
stimulation. (C) Western blot of cyclin D1, PCNA and osteopontin after PDGF
stimulation. (D) Quantification of C, n=3, *p<O.05 vs. control.
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PCNA Cyclin01 Osteopntin

PDGF-induced os teop on tin expression is dependent on glycolysis: To

determine whether the increase in glycolytic flux caused by PDGF stimulation is
important for proliferation and expression of the key synthetic gene osteopontin,
we stimulated VSMCs with PDGF in the presence of koningic acid. As shown in
Figures 11A-C, koningic acid inhibited PDGF-induced VSMC proliferation. PDGF
stimulation of VSMCs caused significant increases in mRNA (14-fold increase)
and protein levels (2.5-fold increase) of osteopontin and these were inhibited by
koningic acid (Figures 11D-F). These findings are all consistent with published
data implicating the role of osteopontin in VSMC proliferation [201] and are novel
because it is the first time that it is being directly shown that glycolytic flux is
important in PDGF induced VSMC osteopontin expression.
Koningic acid treatment increases protein-O-GlcNAc formation: We treated

VSMCs with different concentrations of KA and monitored protein O-GlcNAc
formation. We found that protein O-GlcNAc formation was increased (Figure 12).
This suggested to us that increased protein O-GlcNAc formation might be a
unique mechanism regulating OPN expression and VSMC proliferation.
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Figure 10. PDGF-BB induces increase in glycolytic flux. A) Extracellular flux
analysis after PDGF stimulation. B) Quantification of basal and maximal ECARs
after PDGF stimulation (n=5, *p<O.05 vs. control).
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expression: Because changes in protein O-GlcNAc were observed after POGF
and KA stimulation, we further studied the role of increased O-GlcNAc formation
in POGF-induced VSMC proliferation and osteopontin expression. Increasing flux
to the HBP results in increased activity of the enzyme O-GlcNAc transferase
(OGT) [226] that attaches GlcNAc moieties to protein molecules [220]. 0GlcNAcase removes these GlcNAc moieties

in a reverse reaction [219]. The

global levels of protein O-GlcNAcylated can thus be increased by either,
increasing flux into the HBP (increasing OGT activity) or by inhibiting the enzyme
O-GlcNAcase. We therefore treated VSMCs with Thiamet-g to determine the
effects of increasing protein O-GlcNAc formation on VSMC proliferation and OPN
gene expression.

At non-toxic doses, Thiamet-g caused a concentration

dependent increase in protein O-GlcNAc formation (Figure 13A-0). This increase
in protein O-GlcNAcylation resulted in inhibition of proliferation induced by POGF
(Figure 14A) and expression of cell cycle proteins PCNA and cyclin 01 (Figures
14B-0).
To verify whether the anti-proliferative effect of Thiamet-g was due to impaired
upstream POGF signaling, we measured the phosphorylation status of Akt and
Erk1/2 proteins which are activated upon POGF stimulation and are known to
mediate POGF mitogenic effects in VSMCs [50]. As shown in Figure 15,
Thiamet-g caused no observable difference between POGF stimulated and
unstimulated groups. This further confirmed that increasing protein O-GlcNAc
formation inhibits proliferation by inhibiting expression of cell cycle proteins and
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not by interrupting upstream POGF signaling. We further measured expression of
the synthetic cytokine, OPN, in the presence of Thiamet-g. As shown in Figure
16, osteopontin mRNA expression was inhibited in the presence of thiamet-g.
This result is consistent with the effect of KA on POGF-induced VSMC
proliferation and OPN expression and suggests that the anti-proliferative effect of
Thiamet-g may be mediated in part by inhibition of OPN expression.
Because the expression of cell cycle proteins, PCNA and cyclin 01 were
inhibited by thiamet-g, we went further to determine if Thiamet-g had any effect
on cell cycle progression. Using propidium iodide staining, we found that in the
presence of Thiamet-g, POGF stimulated cells showed significantly slower
progression into the Sand G2/M phases of the cell cycle (Figure 17).
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Figure 11. PDGF-induced glycolytic flux is required for proliferation and
osteopontin expression. A-C) Effects of koningic acid on POGF-induced
proliferation. Serum starved VSMCs were treated for 24 with POGF (20ng/ml) in
the absence or presence of koningic acid (0.5IJg/ml). Cell proliferation was
measured using MTT assay (A) or by counting cell numbers (8). C) LOH assay
after koningic acid treatment. Concentration dependent effects of koningic acid
on cytotoxicity. *p<0.05 vs control (0 IJg/ml koningic acid). D) Quantitative real
time PCR. Osteopontin mRNA expression in the presence of koningic acid ±
POGF. Serum starved VSMCs were stimulated with POGF ± koningic acid for
24h and gene and protein abundance measured by real time PCR (0) and
immunoblotting (E and F), respectively ( n=3, * p<0.03 vs. control).
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Figure 12. Inhibiting glycolytic flux increases HBP flux. Immunoblot analysis

of protein O-GlcNAc formation after koningic acid treatment. A) Increase protein
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Discussion

The present study shows a role for glycolysis in PDGF-induced osteopontin
expression and PDGF-induced VSMC hyperplasia. This study also demonstrates
the importance of protein O-GlcNAc modification in regulating PDGF-induced
hyperproliferation. Using the inhibitor of glycolysis, koningic acid, we found that
after PDGF treatment,

the expression

of the

proinflammatory cytokine

osteopontin was inhibited. Interestingly, inhibiting glucose flux into glycolysis by
KA treatment led to increased protein O-GlcNAc formation. Independently
increasing the levels of protein O-GlcNAc formation by inhibiting the enzyme 0GlcNAcase also led to the inhibition of osteopontin expression and expression of
cell cycle proteins PCNA and cyclin D1 causing the delay of cell cycle
progression. These findings uncover a new role of glycolysis and O-GlcNAc
protein modification in regulating the expression of the synthetic cytokine
osteopontin and in regulating VSMC proliferation.
Regulation of osteopontin expression is known to be under the influence of
different transcription factors. For example, CREB, NFAT, AP-1, USF, SP1, Myc
and Oct-1 are known to regulate osteopontin expression after PDGF stimulation
and osteopontin expression is necessary for some PDGF-induced changes in the
VSMCs [114, 201, 227-229]. Some of these transcription factors are under the
control of cellular glucose levels and glucose uptake, and glycolysis is known to
increase VSMC hyperplasia induced by PDGF [198, 201]. However, the role of
glycolysis in OPN expression has remained unclear.
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Other pathways of glucose metabolism such as the polyol pathway are known
regulators of VSMC hyperplasia. In fact, administering sorbinil, an aldose
reductase inhibitor, prevented VSMC hyperplasia in culture and after balloon
injury of the carotid artery [230-231] indicating an important role of this pathway
in VSMC hyperproliferation. Also, although controversial, the HBP has been
implicated in VSMC hyperplasia and neointima [203, 222-223]. Here, we present
data that supports an anti-proliferative role of increasing protein O-GlcNAc. Our
studies highlight new findings implicating the role of glycolysis and protein 0GlcNAc in OPN expression. We showed that increasing protein O-GlcNAc
formation has an inhibitory effect on VSMC hyperplasia and this inhibitory effect
could be mediated, in addition to inhibiting cell cycle protein expression, through
decreased OPN expression.
The fact that protein O-GlcNAc formation was increased in the presence of KA
suggests that glucose metabolism can be regulated and redirected into a
different pathway upon perturbation in one pathway. The increased protein 0GlcNAc formed after koningic acid treatment suggests that the antiproliferative
effects of inhibiting glycolysis (i.e., by KA treatment) could be mediated in part by
protein O-GlcNAc formation. These are important observations although the
molecular mechanism(s) leading to these observed effects have not been
rigorously tested. However, it is possible that the changes in glucose metabolism
caused by PDGF regulates glucose-controlled transcription factors such as
upstream stimulatory factor (USF) leading to inhibition of osteopontin expression
and VSMC proliferation. We noticed that progression of the cell cycle through
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the S-phase was significantly delayed in the presence of thiamet-g thereby
suggesting that mechanisms regulating S-phase transition could have been
inhibited. The inhibitors, koningic acid and thiamet-g did not alter PDGF-induced
autophagy (observed in chapter II) or PDGF-induced degradation of contractile
proteins thereby suggesting that the process of cellular degradation during
phenotype switching

might simultaneously be occurring

via

a pathway

independent of osteopontin expression and proliferation.
In summary, the study presented in this section identifies possible roles of
glucose metabolic pathways in regulating VSMC proliferation and osteopontin
expression. This study highlights the importance of glucose metabolism in
attaining the fully synthetic phenotype characterized by, in addition to decreased
contractile protein expression, increased osteopontin expression and increased
proliferation. Our study suggests possible therapies that could be developed and
used (in drug eluting stents) to curb VSMC hyperproliferation. Future studies are
needed to delineate the complete mechanism by which these inhibitors produce
their effects.
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Figure 13. Thiamet-g

increases protein

O-GlcNAcylation

in VSMCs.

Immunoblot analysis of protein O-GlcNAc formation after thiamet-g treatment. A)
Serum

starved

VSMCs were treated

with

Thiamet-g

at the

indicated

concentrations. B) Densitometric quantification of A (n=3, *p<O.03 vs OIJM). C

and 0) Cytotoxicity due to Thiamet-g treatment. Cell toxicity was measured using
the MTT assay and the LDH assay (*p<O.01 vs control). Thapsigargin was used
as a positive control to induce cell death.
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Figure 14. Increased protein O-GlcNAcylation inhibits PDGF-induced VSMC
proliferation. Cell proliferation assay. (A) Serum starved VSMCs were treated
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(8) Expression of cell cycle proteins.

Immunoblot analysis of PCNA and cyclin 01 abundance after POGF ± treatment.
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Figure 17. Thiamet-g causes delayed cell cycle progression. Cell cycle
analysis with propidium iodide. VSMCs serum starved for 24h and then
stimulated with PDGF or PDGF + Thiamet-g for the indicated time points. Cell
cycle progression was monitored using a C6 Accuri flow cytometer (n=3,
*p<O.001 for PDGF vs PDGFfThiamet-g).
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CHAPTER IV
MITOCHONDRIA FISSION REGULATES METABOLISM AND VSMC
PROLIFERATION
Introduction

Rapidly proliferating cells require an increase in energy production and elevated
formation of metabolic intermediates. These demands can be achieved by
increasing the metabolism of major substrates such as glucose, glutamine or
fatty acids. In synthetic VSMCs which are not only rapidly dividing, but are
migratory and secreting ECM, the requirements for cellular energy are even
higher. To meet with these demands, synthetic VSMCs could increase their
overall metabolic flux or switch to oxidizing metabolic substrates that provide
more energy. Thus, metabolizing more efficient substrates, such as fatty acids
could be an efficient means of satisfying cellular needs during excessive
proliferation and migration.

Mitochondria are the cellular hubs of metabolism and have the capacity of both
changing their substrate preference as well as their morphology.

Previously,

mitochondria were regarded as static organelles with the principal function of
producing ATP needed for cellular respiration. However, with the discovery of
different proteins that regulate mitochondrial morphology, these organelles are
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now known to be dynamic and capable of changing their morphology to regulate
different cellular processes, such as calcium handling [232] and apoptosis [233].
During cell proliferation, mitochondria form giant networks which are known to be
associated with increased ATP formation [234]. This network formation typically
occurs during the G1 to S transition of cell cycle in which the cellular glycolytic
rates are low. Thus, mitochondria network formation maximizes energy
production during these times of increased synthetic activity.

A number of mitochondria related proteins are now known to regulate
mitochondria morphology. For example dynamin related protein 1 (DRP1) and
human mitochondria fission protein 1 (hFis1) promote mitochondria fission [235236]. Conversely, mitofusins 1 and 2 (Mfn1 and 2) and optic atrophy 1 (Opa1)
promote

mitochondrial

fusion.

Changes

in

mitochondrial

morphology

(mitochondrial fragmentation) occurs in apoptotic cell death [237-238]. Recent
studies have shown that mitochondrial morphology is instrumental in the process
of mitophagy whereby long tubulated mitochondria are spared from incorporation
into the autophagosome [239]. Mitochondrial morphology in diseased conditions
such as ischemia reperfusion injury, diabetes, cytosolic calcium overload, heart
failure and dilated cardiomyopathy has also been studied [240-243]. However,
the role of mitochondria in the VSMC during phenotype conversion has not been
given great attention with only a few recent studies suggesting a role of Mfn2,
Drp1 and mitochondria morphology in VSMC hyperproliferation under diseased
conditions [244-245].
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In this study, we examined the effects of PDGF on mitochondrial morphology and
metabolism. We found that synthetic VSMCs utilize increase fatty acid oxidation
(FAO) in response to PDGF which was preceded by mitochondria fragmentation.
Mitochondria fragmentation induced by PDGF was accompanied by decreased
expression of the pro mitochondria fusion gene mitofusin 2 thereby suggesting a
mitofusin 2-mediated mechanism. Mitochondria fragmentation was necessary for
increased FAO and increased proliferation because mdivi-1, an inhibitor of
mitochondria fragmentation, prevented PDGF-induced FAO and proliferation.
This increase in FAO was not due to an increase in mitochondria content
because the total mitochondria abundance did not change in the synthetic cells.
Collectively, these data demonstrate that substrate switching to FAO is important
in generating energy needed for the synthetic VSMC and identifies mitochondria
fragmentation as an important process critical for VSMC proliferation after PDGF
stimulation.
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Experimental procedures

Materials

Reagents: Antibodies against VDAC, COX IV and ATP synthase 13 were

obtained from Novus Biologicals (Littleton, CO, USA). The Mito ID red dye and
Hoechst stain were obtained from Enzo life sciences (Farmingdale, NY, USA).
Etomoxir, FCCP, antamycin A and rotenone were obtained from Sigma Aldrich
(St. Louis, MO, USA). Rabbit polyclonal antibody against rat Mfn2 was obtained
from Abcam. Recombinant FGF-1 was obtained from eBiosciences (San Diego,
CA, USA). Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and
a-tubulin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit
polyclonal

antibody

against

LC3

was

purchased

from

Cell

Signaling

Technologies (Danvers, MA, USA). Propidium iodide was purchased from
eBiosciences (San Diego, CA, USA).
Cell culture: Rat aortic smooth muscle cells (RASMCs) were isolated from the

aortas of 6 weeks old male Sprague-Dawley rats and grown in DMEM
(Dulbecco's
supplemented

modified
with

Eagle's

10%

(v/v)

medium;
FBS

Life

(foetal

Technologies-Invitrogen)

bovine

serum)

and

0.1 %

streptomycin/penicillin. Cells used in experiments were from between passages
2-7 maintained in a humidified atmosphere of air and 5% CO 2 at 37 cC. At about
70% confluency, RASMCs were serum starved in DMEM containing 0.1 % FBS
for 24 hours. After desired treatments, cells were rinsed twice with phosphate
buffered saline and then lysed in a protein lysis buffer containing 25 mM HEPES,
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1 mM EOTA, 1 mM EGTA, 0.1% SOS, 1% NP-40, 1x protease and phosphatase
inhibitors. Lowry's assay was used for measuring protein concentration of crude
cell extracts.
Western blotting: For Western blotting, between 0.5-25 I-1g of crude cell protein
was applied to each lane of a 10.5-14% Bis-Tris gel and electroblotted onto a
PVOF membrane. The membrane was then incubated overnight at 4°C using
appropriate dilutions of primary antibodies. The PVOF membranes were
incubated

at

room

temperature

with

horseradish

peroxidase-conjugated

secondary antibodies. Immunoreactive bands were detected with enhanced
chemiluminescent detection reagent (GE Healthcare).
Confocal Imaging: Cells plated on glass-bottom dishes were serum starved for
24h in 0.1 % FBS OMEM. Cells were then stimulated with POGF and desired cotreatments for the desired times. For visualization, mitochondria were stained
using the mito 10 kit from Enzo life sciences (Farmingdale, NY, USA) following
the specified protocol. Mito 10 and Hoechst stains were diluted in phenol red-free
OMEM supplemented with 25 mmol/L HEPES, pH 7.4) and then added to cells
for 10 mins. For imaging, cells were illuminated with desired laser and images
acquired using a 60x objective lens covered with a thin layer of oil.
Measurement of cellular energetics using the XF24 extracellular flux
analyser: Cellular energetics was measured in intact VSMCs using a Seahorse
Bioscience XF24 extracellular flux analyzer. Fifty thousand cells were seeded in
12-wells of a 24-well XF plate (Control group), while twenty five thousand cells
were seeded in the remaining 12 wells (POGF treated group). Cells were then
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serum starved in 0.1 % FBS DMEM for 24h and then stimulated with 20 ng/ml
PDGF in the same media for 48 h. After PDGF stimulation, media was replaced
with DMEM containing 100 !-1M BSA-palmitate, 1mM pyruvate, 5 mM D-glucose,
and 100 !-1M L-carnitine. After equilibration in the media, the cells were exposed
to etomoxir and OCR was measured. Data obtained were normalized to the
amount of protein present in the well of the microplate. For normalization, cells
were lysed in the 24-well XF plates using 20 pi/well of protein lysis buffer. Protein
concentration was then measured using the Lowry's method.

Cell proliferation assays and measurement of cell viability: Vascular smooth

muscle cells were serum starved for 24h in order to synchronize cells in the GO
phase. After serum starvation, cells were treated for the required duration as
indicated. After treatment, cells were rinse twice with PBS and then trypsinized
with a 0.25% trypsin solution for about 3 minutes at 37°C. Cells were then resuspended in DMEM containing 10% FBS and cell numbers were determined
using a C6 Accuri flow cytometer. For viability assays, after desired treatment,
cells were incubated in a solution of 0.2 mg/ml MTT reagent for 2-4 h at 37°C in
an incubator containing 5% C02. After incubation, MTT reagent was then
aspirated and the purple crystals at the bottom of the plate dissolved in DMSO.
Absorbance at 540 nm was then measured using a microplate reader.
Cell cycle studies with propidium iodide: VSMCs were harvested after 3 min

trypsin incubation, washed with phosphate buffered saline (PBS) and cold 70%
ethanol added to the cells. VSMCs were then kept at 4°C for 1 hour to fix cells.
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After fixing, cells were sedimented at 500 x g for 5 mins and the supernatant
discarded. Cells were then washed again with PBS and 300 IJI RNase buffer
containing 5 IJI propidium iodide added after all residual PBS has been
discarded. Cells were then mixed and incubated at room temperature for 45 min
after which they were analyzed using a C6 Accuri flow cytometer.

Statistical analysis: Data are mean ± SEM. Experimental groups were compared

using one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's
test was used for direct comparisons. A p-value <0.05 was considered significant.

Results

Synthetic VSMCs show increased fatty acid oxidation and mitochondria
fragmentation: To examine energetic changes that occur in synthetic VSMCs,

we measured fatty acid oxidation (FAO) after PDGF stimulation. We serum
starved VSMCs and then converted one group to the synthetic phenotype by
PDGF treatment for 48 h, while the other group was left untreated.

Oxygen

consumption was then measured in media containing L-carnitine and only BSApalmitate and glucose as available substrates. To interrogate the contributions of
FAO and glucose oxidation to the overall oxidative phosphorylation, we added
etomoxir into the media and then monitored oxygen consumption rates (OCRs).
Etomoxir is an inhibitor of carnitine palmitoyl transferase 1, an enzyme needed
for conjugating and translocating long chain fatty acids from the cytoplasm to the
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t-

mitochondria where they are committed to p-oxidation [246]. Addition of etomoxir
should therefore cause a drop in OCR and this drop in OCR will be due to
inhibition of p-oxidation or FAD (see scheme 5).

As shown in Figure 18,

etomoxir injection decreased in OCR to a greater extent in PDGF treated cells
compared with control cells, thereby indicating an increase in FAD in synthetic
cells. This increase in FAD could not be due to differences in the amount of cells
nor changes in mitochondria abundance because the results were normalized to
protein expression per well and because a Western blot analysis of mitochondria
content showed no differences between the synthetic and contractile phenotypes
(Figure 19).
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* 100

Figure 18. PDGF treatment increases fatty acid oxidation in VSMCs. Oxygen

consumption

measurements

in

contractile

and

synthetic

VSMCs

A)

Representative extracellular flux measurements. VSMCs were serum starved for
24 h and then left untreated or converted to the synthetic phenotype by PDGF
stimulation for 48 h (OCR drop after etomoxir injection is fatty acid linked). OCRs
were normalized to total proteins. B and C) Quantification of A. (Total oxidative
phosphorylation activity = (point 7 - point 8). Percent oxygen consumption due to
FAO = (point 3 - point 4)/ (point 7 - point 8)*100. Percent due to GO = (100 %FAO), see scheme 5. (n=3, *p<0.05 vs control i.e. contractile cells).
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Figure 18
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76

Figure 19. Increased FAO in synthetic VSMCs is not due to increased
mitochondria abundance. Total mitochondria abundance was not changed

upon conversion to the synthetic phenotype. A) Representative Western blot.
VSMCs were starved for 24 h and then treated without or with PDGF for 48 h. BE) Quantification of A, (n=3 independent experiments).
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Figure 19
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It was recently reported that changes in mitochondrial morphology and network
formation play important roles in energy production and proliferation of VSMCs
[247-248]. We therefore went further to determine whether the observed change
in substrate utilization was accompanied with
morphology.

changes in mitochondria

As shown in Figure 20A, synthetic VSMCs had mainly small

rounded or fragmented mitochondria (globular) as opposed to contractile cells
whose mitochondria were mainly filamentous and network forming. The
expression of mitofusin 2, a pro-mitochondria fusion gene, was down regulated in
synthetic cells thereby suggesting a mitofusin 2-dependent mechanism of
mitochondrial fragmentation (Figure 20C and D). Interestingly, this change in
mitochondria shape and substrate utilization was specific to cells stimulated with
PDGF because FGF-1 neither increased FAO nor did it cause mitochondrial
fragmentation (Figure 21).

Mitochondria fragmentation causes increased FAD in synthetic VSMCs: To
determine whether changes in mitochondria morphology influenced substrate
usage in synthetic cells, we stimulated VSMCs with PDGF in the presence of the
mitochondria fission inhibitor (DRP1 inhibitor), mdivi1 [249] and measured
changes in OCR after etomoxir injection. As shown in Figures 22A and B, mdivi1
inhibited the fragmentation caused by a switch to the synthetic phenotype. This
inhibition also prevented the switch to FAO observed upon conversion to the
synthetic phenotype (Figures 22C and D). The inhibition of mitochondria
fragmentation caused

a complete blockage of PDGF-induced proliferation by
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decreasing the expression of cell cycle proteins cyclin D1 and PCNA and stalling
cells in the s-phase of the cell cycle (Figure 23).
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Figure

20.

PDGF

induces

mitochondria

fragmentation

in

VSMCs.

Mitochondria morphology in contractile and synthetic VSMCs. A) Representative
live cell confocal images of untreated or 48 hour PDGF treated cells. B)
Mitochondrial morphologies. Mitochondria lengths were measured using the NIS
Elements software and scored as follow: Mitochondrial morphology was scored
as follows: Globular, mainly small and round « 2 IJm in diameter); intermediate,
between 2-4 IJm in length; and filamentous, long and higher interconnectivity (> 4
IJm in length). The percentage of cells with indicated mitochondrial morphologies
was determined as a percentage of the total number of stained cells counted
(~150

cells per experiment), n = 4 independent experiments, blue = hoechst, red

= mito ID red. (Scale bar: 10 IJm). C) PDGF-induced mitochondria fragmentation
is associated with loss of mitofuscin 2. Representative Western blot analysis of
mitofusin 2 expression after PDGF time course stimulation. D) Quantification of
C, (n=3 independent experiments, *p<0.05 vs ctrl).
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Figure 20
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Figure 21. FGF-1 does not induce mitochondria fragmentation/fatty acid
oxidation. Mitochondria morphology and FAO in VSMCs exposed to FGF-1. A)
Representative extracellular flux measurements. VSMCs were serum starved for
24h and then stimulated with FGF-1 for 48 h. B and C) Quantification of A. Total
oxidative phosphorylation activity = (point 7 - point 8). % oxygen consumption
due to FAO

=(point 3 -

point 4)/ (point 7 - point 8)*100. % due to GO

%FAO). 0) Mitochondria morphology after FGF exposure.
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To verify if mitochondrial fragmentation acts upstream of FAD, we stimulated
cells with PDGF in the presence of etomoxir and then measured changes in
mitochondrial morphology. As shown in Figure 24, etomoxir inhibited PDGFinduced proliferation but had no effect on mitochondria fragmentation, suggesting
that mitochondria fragmentation precedes increases in FAD and proliferation.
Dur results suggest that VSMCs in the synthetic phenotype increase FAD and
this increase in FAD is regulated by mitochondria morphology because only the
globular (fragmented) mitochondria phenotype was associated with increased
FAD.

PDGF-induced contractile protein degradation during phenotype switching
is NOT dependent on mitochondria fragmentation and FAO: We previously

determined that conversion to the synthetic phenotype required induction of
autophagy, which is needed for the degradation of contractile proteins such as
calponin

and

a-SM

actin

(Figure

5).

Since

inhibition

of mitochondria

fragmentation inhibited PDGF-induced proliferation and because increased
proliferation is associated with the synthetic phenotype, we wanted to verify if
mitochondrial fragmentation and increased FAD were required for PDGF-induced
contractile protein degradation leading to the emergence of the synthetic
phenotype. As shown in Figure 25, inhibition of PDGF-induced fragmentation did
not affect degradation of contractile proteins suggesting that contractile protein
degradation is not dependent on changes in mitochondrial morphology and
increased FAD. We went further to determine whether inhibiting PDGF-induced
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autophagy (or contractile protein degradation) would affect mitochondrial
fragmentation. Also, Spautin1, an inhibitor of autophagy, did not inhibit PDGF
induced fragmentation. These data suggest that contractile protein degradation
and mitochondria fragmentation occur via separate pathways. The relative
contributions of these pathways lead to the emergence of a fully dedifferentiated
VSMC characterized by decreased expression of smooth muscle cell contractile
proteins, increased proliferation and other synthetic characteristics such as
increased migration and ECM synthesis (see Scheme 6).

Discussion

Our present study shows that mitochondrial morphology is important for
regulating substrate usage and VSMC proliferation in the synthetic phenotype.
We demonstrated that conversion of VSMCs into the synthetic phenotype is
accompanied

by

increased

FAO

which

is

preceded

by

mitochondrial

fragmentation. This change in mitochondria morphology appears to be required
for increasing FAO and proliferation, as mdivi1 inhibited both mitochondrial
fragmentation and proliferation. We also found that although the change in
substrate metabolism was required for increased proliferation, it did not have any
effect on PDGF-induced contractile protein degradation. These findings uncover
mitochondrial fragmentation as one of many extensive cellular changes occurring
during conversion into the synthetic phenotype.
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Beta oxidation of long chain fatty acids occurs in the mitochondria and yields two
times more ATP per gram when compared with glucose or amino acids [250251]. Thus, under conditions of excessive energy demand, cells are more likely
benefit from FAO. Since long chain FAs cannot freely diffuse through the
mitochondrial inner membrane, a transport system is required. This transport
system comprises a group of enzymes known as carnitine palmitoyl transferases
(CPT) [252]. CPT1, the rate limiting enzyme of the CPT system [252], catalyses
the transfer of an acyl group from coenzyme A on an activated FA to carnitine to
form palmitoylcarnitine. Palmitoylcarnitine is then shuttled across the inner
mitochondria membrane where it is converted back into palmitoyl-CoA. PalmitoylCoA can be broken down to acetyl-CoA which enters the TCA cycle to yield ATP
and the reducing equivalents NADH and FADH2 [253]. We found that etomoxir,
an inhibitor of CPT1, inhibited PDGF-induced VSMC proliferation but not
mitochondria fragmentation.
We proposed that changes in mitochondria morphology induced by PDGF
regulate substrate utilization. Changes in substrate metabolism could lead to
increased glycolysis (resulting in increased flux of pyruvate into mitochondria) or
could lead to increased FA utilization or both. Interestingly, we found that in
addition to increased glycolysis after PDGF stimulation of VSMCs, FAO was also
increased. These combined increases in glycolysis and FAO may be important
for supporting energy requirements and cellular changes in the fully synthetic
phenotype.
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Previous studies in other cell types show that promotion of mitochondrial fission
by knock down of Mfn2 leads to reduced mitochondrial membrane potential, less
oxidative phosphorylation and increased dependency on glycolysis, possibly
mediated through reduced expression and activity of different subunits of the
electron transport chain [254]. In the case of POGF-induced mitochondrial
fragmentation, we found that the overall oxidative phosphorylation of both
contractile and synthetic cells remained the same and there were no changes in
expression of the subunits in the electron transport chain (Figure 19).
Mitochondria fission was found to be important in POGF-induced proliferation
through a mechanism involving regulation of expression of cell cycle proteins
such as PCNA and cyclin 01. In fact, in the presence of Mdivi1, the expression of
PCNA and cyclin 01 were inhibited and cells became stalled in the S-phase.
However, it remains to be clearly elucidated whether the effects of Mdivi1 on
proliferation are linked to its mitochondria-fission-inhibitory effect or due to a
different effect. It is however important to note that the effects on proliferation
observed with Mdivi1 concur previous findings showing that promotion of
mitochondria fusion through overexpression of Mfn2 promote inhibition of VSMC
proliferation [244].
Collectively, these studies provide novel insights into the role of mitochondria in
POGF-induced proliferation. Mitochondria morphology is a determinant of
substrate usage but not of protein degradation during phenotype switching.
Identification of the role of mitochondria in VSMC opens new avenues for
therapeutic management of atherosclerosis and restenosis.
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Figure 22. PDGF-induced mitochondrial fragmentation results in increased
FAO. Inhibition of mitochondria fission inhibits PDGF-induced fragmentation and
FAD. A) Representative confocal images of serum starved VSMCs treated
without or with PDGF ± Mdivi-1. Morphology is shifted towards the filamentous in
the presence of Mdivi1. B) Quantification of A. Fil = filamentous, Glo = Globular
and Int = Intermediate.

(~150

cells counted per experiment, experiment was

repeated at least two times). C) Representative extracellular flux measurements.
VSMCs were serum starved for 24h and then left untreated or converted to the
synthetic phenotype by PDGF treatment for 48h ± Mdivi1. D) Quantification of C
(n=4 independent experiments, *p<O.05 vs ctrl, &p<O.05 vs PDGF).
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Figure 23. Inhibition of mitochondrial fragmentation decreases PDGFinduced proliferation. A) Cell proliferation after PDGF ± mdivi1 treatment.
VSMCs were serum starved for 24 h and then treated for 24 h (n = 5 per
treatment group, *p<O.03 vs control, &p<O.01 vs PDGF). B) Inhibition of cell cycle
protein expression by mdivi1. VSMCs were serum starved for 24h and then
stimulated with PDGF for the indicated times in the absence or presence of
mdivi1. C and D) Quantification of B (n = 3 per treatment group, *p<O.05 vs
untreated). E) Cell cycle analysis using propidium iodide. Mdivi1 stalls cells in the
S-phase of cell cycle. Cells in upper panel were stimulated with PDGF for the
indicated times while cells in the lower panel were stimulated with PDGF but in
the presence of mdivi1.
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Figure 24. FAO is required for PDGF-induced proliferation. Etomoxir inhibits

PDGF-induced proliferation. A) Concentration dependent effect of etomoxir on
VSMC proliferation. Cell proliferation was measured by counting cell numbers
using the Accuri C6 flow cytometer (n=6, *p<O.05 vs untreated). B) Cell viability
by MTT assay. VSMCs after exposure to different concentrations of etomoxir
(n=6, ***P<O.01 vs control). C) Effects of FAD on mitochondria fragmentation.
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Figure 25. Mitochondria fragmentation and FAO are not prerequisites for
POGF-induced contractile protein degradation. Mdivi1 does not inhibit PDGFinduced autophagy and contractile protein degradation. A) Representative
immunoblot after PDGF ± mdivi1 treatment. Cells were serum starved for 24h
before treatment. 8-0) Quantification of A (n=3, *P<O.05, **p<O.01 vs untreated).
E) FAO is not required for PDGF-induced autophagy and contractile protein

degradation. Representative immunoblot after PDGF ± etomoxir treatment.
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CONCLUDING DISCUSSION

Our studies were aimed at developing a better understanding of how metabolism
regulates VSMC phenotype. For this, we examined processes relating to protein
degradation and studied metabolic changes occurring during and after VSMC
phenotype transition. We proposed that in addition to inducing other cellular
processes needed for the conversion to the synthetic phenotype, PDGF induces
autophagy as a means to degrade unwanted cellular components, making way
for the emergence of a fully synthetic phenotype. We also proposed that PDGF
stimulation regulates cellular metabolism to increase energy production which
supports proliferation and synthetic VSMC activity.

In the first set of experiments we wanted to determine which protein degradation
pathways are primarily involved during phenotype switching. We examined the
proteasomal and the autophagic pathways - the predominant pathways of
cellular degradation in mammalian cells. We found that inhibition of the
proteasomal

pathway

had
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limited

effects

on

PDGF-induced degradation of calponin and sm-a-actin. This suggested to us that
the autophagic pathway of protein degradation could be involved during
phenotypic conversion.
The conversion to the synthetic phenotype requires rapid cellular changes and
degradation of contractile proteins, which would be thought to require proteolytic
pathways such as autophagy or the proteasome. In mammalian cells, autophagy
is known to be the major pathway through which cellular contents are degraded
during growth and transformation. We therefore examined the role of autophagy
during phenotype transition. In chapter II, we presented data showing that PDGF
promotes autophagy in VSMCs. The induction of autophagy by a mitogen is
atypical, because other growth factors (e.g., insulin) have been shown to inhibit,
rather than activate, autophagy. PDGF-induced autophagy appears to be
important in phenotype switching because inhibition of autophagy with different
structural inhibitors led to stabilization of calponin and sm-a-actin. This appears
to be specific to PDGF because other mitogens such as FGF-1 neither induced
autophagy nor promoted phenotypic switching.

Interestingly, PDGF-induced autophagy was protective against HNE-induced
toxicity. This is consistent with multiple studies showing that autophagy is a
survival response activated during starvation and under conditions of oxidative
stress. Because HNE is a constituent of atherosclerotic lesions known to form
protein-HNE adducts and to cause cytotoxicity, the heightened autophagy in
synthetic cells could render these cells stress resistant hence enhancing plaque
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stability during atherogenesis. Our findings therefore support the notion that
(mitogen-mediated) autophagic induction in VSMCs could be protective,
therefore exposing new therapeutic avenues. However, in the context of
atherosclerosis, the manipulation of autophagy for therapeutic success should be
approached with caution because induction of autophagy can be maladaptive as
well. For example, excessive induction of autophagy might eventually trigger
autophagy-induced cell death or type 2 cell death, resulting in increased plaque
destabilization [255].

The induction of autophagy during phenotypic conversion may also be
advantageous to the rapidly proliferating synthetic cell. Since autophagy
degrades cellular components to their constituent amino acids, these could be
used as building blocks for different and new macromolecules prevalent in the
synthetic cells. The importance of autophagy in this regard could be seen from
the findings that inhibiting autophagy decreased VSMC proliferation, a key
feature of the synthetic phenotype. Our findings therefore suggest a role of
autophagy in VSMC proliferation. This novel role could also be exploited for
therapeutic advantage in vasculo-proliferative complications such as restenosis
[27].

In chapter III, we found that an increase in glycolytic flux after PDGF treatment
does not only increase mitochondrial activity [145], but it is also required for the
expression of the synthetic gene OPN. OPN is a cytokine secreted by synthetic
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VSMCs and it is known to promote plaque formation by promoting VSMC
migration into intima. Our findings therefore suggest a possible link between
glycolysis and vascular lesions caused by VSMC hyperproliferation. Our findings
also confirm previous findings implicating the role of glucose-regulated
transcription factors in OPN expression.

POGF-induced OPN expression was also partly regulated by O-GlcNAc
formation. Increasing O-GlcNAc formation via Thiamet-g treatment inhibited
POGF-induced OPN expression. This finding supports previous findings
suggesting an inhibitory role of increased HBP flux (or O-GlcNAc) in VSMC
hyperproliferation.

However,

in

hyperglycemic

conditions

such

diabetes,

increased flux into the HBP has been thought to contribute to VSMC
hyperproliferation and has been associated with an increased incidence of CVO.
Our results therefore suggest the contrary because increased levels of O-GlcNAc
(an end product of increased HBP flux) had inhibitory effects on VSMCs.
However, it is worth noting that increased flux to the HBP does not necessarily
imply an increase in (protein) O-GlcNAc formation. Also, the diabetic condition is
not only characterized by increased glucose flux into the HBP, but also by other
conditions such as increased levels of circulating free fatty acids.
The increased O-GlcNAc formation observed after Thiamet-g treatment was
associated with delay in cell cycle progression and decrease expression of cell
cycle proteins cyclin 01 and PCNA.

Thiamet-g-treated cells were stalled

between the G1 and S-phases of cell cycle. Since O-GlcNAc modification is a
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posttranslational modification, the inhibitory effects of this modification on cell
cycle proteins could cause cell cycle arrest. It remains to be determined whether
D-GlcNAc has a direct modifying effect on cell cycle proteins or its effects on cell
cycle progression are mediated via other intermediary proteins. Furthermore,
more experiments are needed to rigorously test the contribution of the HBP and
protein D-GlcNAc formation in vascular complications under normal and diabetic
conditions.

In chapter IV, we found that intermediary metabolism plays an important role in
PDGF-induced phenotype transition. Specifically, we found that synthetic VSMCs
show increased FAD and decreased rates of glucose oxidation (described in
chapter III). This increase in FAD was preceded by changes in mitochondrial
morphology. The increases in FAD may be required to meet the high energy
demands of synthetic cells.

In the synthetic state, VSMCs had mostly rounded or fragmented mitochondria
compared with the long filamentous mitochondria found in contractile cells. It has
been previously reported that filamentous mitochondria form giant networks that
are associated with increased ATP production and that these networks can
evade autophagic degradation under conditions of starvation. Here, however, we
found that the fragmented mitochondrial phenotype may instead be associated
with increased ATP production (since it utilizes more fatty acids). This increase in
FAD in synthetic cells could be as a result of increased total mitochondria
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surface area or increased expression (or activation) of proteins involved in FAO
such as CPT1. The fragmented mitochondria (as well as increased FAO)
contributed to VSMC hyperplasia because mdivi 1 (which promotes fusion)
inhibited proliferation. These findings are consistent with previous studies
showing that promoting mitochondrial fusion in VSMCs, by overexpressing the
pro-fusion gene mitofusin, prevents VSMC hyperplasia, and that the fragmented
mitochondria are predominant in diseased VSMCs such as found in hypertensive
vessels [245, 256]. Inhibition of mitochondrial fragmentation also prevented
increased FAO. This suggests that mitochondrial fragmentation is upstream of
FAO observed upon PDGF stimulation.

During mitosis, mitochondria fragmentation is required to produce equal
mitochondria numbers for the emerging daughter cells. We found that inhibition
of mitochondrial fragmentation caused cells to stall in the S-phase leading to
inhibition of cell proliferation. This inhibition of cell proliferation could be attributed
to: 1) the unavailability of mitochondria for the prospective daughter cells; and 2)
the inhibition of FAO caused by mitochondrial fragmentation. In chapter IV, we
present data supporting the latter because inhibiting FAO led to inhibition of cell
proliferation.

In summary, our results uncover novel mechanisms by which metabolism
regulates VSMC phenotype.

Our data identify autophagy as an important

process regulating phenotypic switching and provide new insights into the role of
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fatty acid metabolism in phenotypic transition. Although the metabolic and
autophagic changes during this transition seem to occur via separate pathways,
these pathways contribute to the emergence of a fully synthetic phenotype
(Scheme 6). These data could form the basis for of the development of more
effective anti-restenotic and -atherosclerotic therapies.

Nevertheless, future

studies are required to decipher the mechanism(s) involved in our observations.
Studies aimed at determining the contributions of other substrates such as
glutamine also warrant our attention, and in vivo studies are required to define
the usefulness of chemical regulators of autophagy, O-GlcNAc and mitochondrial
morphology on VSMC proliferation.
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APPENDIX

NON-STANDARD ABBREVIATIONS AND ACRONYMS

VSMCs

Vascular smooth muscle cells

SP-1

Spautin 1

3-MA

3-methyl adenine

USP

Ubiquitin specific peptidase

PDGF

Platelet-derived growth factor

HBP

Hexosamine biosynthetic pathway

GFAT

Glutamine: Fructose amidotransferase

UDP-GlcNAc

Uridine diphospho-I3-N-acetylglucosamine

O-GlcNAc

13-0-linked N-acetylglucosamine

Ad-GFP

Adenovirus-delivered green fluorescent protein

Ad-GFP-LC3

Adenovirus-delivered green fluorescent protein linked LC3

PUGNAc
OGT

O-(2-acetamido-2-deoxy-d-glycopyranosylidene) amino-Nphenyl carbamate
O-GlcNAc transferase

LDH

Lactate dehydrogenase

MTT

(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)

PCNA

Proliferating cell nuclear antigen
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Mfn2

Mitofusin 2

Mdivi-1

Mitochondria division inhibitor 1

ECM

Extracellular matrix

OPN

Osteopontin

FGF-1

Fibroblast growth factor 1

LC3

Microtubule-associated protein light chain 3

FAO

Fatty acid oxidation

ECAR

Extracellular acidification rate

OCR

Oxygen consumption rate

HNE

4-hydroxy-trans-2-nonenal

CPT1

Carnitine palmitoyl transferase 1

LDL

Low density lipoprotein

TCA

Tricarboxylic acid cycle

KA

Koningic acid

MTC01

Mitochondrially encoded cytochrome c oxidase I

SDHB

Succinate dehydrogenase [ubiquinone] iron-sulfur subunit

ATP5A

ATP synthase subunit alpha

NDFUB8

NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8
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